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ABSTRACT

Over the past few years, pharmaceuticals and endocrine disrupting compounds have been
identified as emerging environmental contaminants, and their presence and persistence in
the aquatic ecosystem at low and yet discernible concentrations (ng/L - pg/L) have been
highlighted. An understanding of the occurrence and behaviour of these compounds in
wastewater and other water matrices is necessary for addressing the risks they pose to the
aquatic environment. As the concern about these non-biodegradable recalcitrant
compounds grows, their removal from water is becoming imperative. This urgent issue
has led to an increasing number of studies on using or adapting various technologies for
treating water contaminated with these compounds.

The present study focused on the detection of the target analytes (ibuprofen and
naproxen) at trace concentrations (ng/L - pg/L) in wastewater and surface water in and
around southwestern Ontario. The study examined the removal of the target analytes from
the various water matrices (laboratory grade water, wastewater effluent, and surface
water) under spiked conditions. The work involved kinetic studies designed to determine
fluence based and time based rate constants. Liquid-liquid extraction followed by
GC/MS, using positive electron ionization mode, was used to analyze and to quantify the
target analytes. A bench-scale study of their degradation was carried out in diverse water
matrices using UV alone and UV/H 2O2 based advanced oxidation process that employed
low pressure (LP) and medium pressure (MP) lamps.

The observed concentrations of the target compounds in wastewater influent ranged from
zero (or below detection) to 17 pg/L, compared to the method detection limits of 0.01
pg/L to 0.045 pg/L. The study found that during LP-UV treatment, the degradation o f
ibuprofen by direct photolysis was 35%-52% of its initial concentration in the three water
matrices, whereas naproxen concentration was reduced by approximately 73%-79%. On
the other hand, when MP-UV treatment was used, ibuprofen concentration was reduced
by 79%-82% and naproxen to levels 91%-99%. Both target compounds degraded to
concentrations below method detection limits following the use of MP-UV in addition to
20 mg/L of hydrogen peroxide. The findings of the study suggest that ibuprofen and
naproxen are present in the London, ON wastewater treatment plant influent. The results
further showed that UV/H 2O2 based oxidation process is a promising technology for the
removal of ibuprofen and naproxen present in a range of water from spiked laboratory
grade water to sewage treatment effluent.

Key W ords: Pharmaceuticals, Non steroidal anti-inflammatory drugs, Ibuprofen,
Naproxen, Wastewater, Surface Water, Photodegradation, UV/H2O2 Advanced
Oxidation Process, Water Absorbance Spectra.
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CHAPTER 1
INTRODUCTION

1.1

Background

One of the first reports of the release of pharmaceutically active compounds (PhACs) into
the aquatic environment was a study conducted in Canada on the concentrations of
selected drugs in the effluent from a Vancouver sewage treatment plant, where two
analgesic/anti-inflammatory drugs, ibuprofen and naproxen, were identified (Rogers et al.
1986).

The detection of clofibric acid, the active metabolite of the lipid regulators clofibrate,
etofyllinclofibrate and etofibrate in wastewaters from sewage treatment plants (STPs)
was first reported in the 1970s (Hignite and Azamoff 1977). Following that, early
investigations of drug residues in the environment often focused on clofibric acid
(Garrison et al. 1976, Richardson and Bowron 1985, Heberer and Stan 1997, Temes et al.
1998, Wilken et al. 2000, Jones et al. 2001). In Germany, clofibric acid has been found
on numerous occasions in surface water, groundwater and tap water (Stan et al. 1994,
Heberer et al. 1995, Stan and Heberer 1997, Heberer et al. 1998, Wilken et al. 2000,
Heberer et al. 2002, Jones et al. 2005b) with reported concentrations up to 270 ng/L
(Heberer 2002b, Jones et al. 2005a) in finished drinking water.

Pharmaceuticals have been detected in environmental water samples in studies conducted
over the past 30 years. A study by Jungclaus et al. (1978) found a small quantity of
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antipyretic, anti-inflammatory drug and antidepressant drug in wastewater and river water
following the detection of lipid lowering clofibric acid in the early 1970’-s in wastewater
(Hignite & Azamoff 1977). During that time Jungclaus et dl. (1978) detected 5-(3Dimethylaminopropyl)- 10, 11-dihydrodibenzo [b, f] azepine at 3.7 mg/L in wastewater
but not in river water. On other hand, 4-n-Butyl-l,2-diphenylpyrazolidine-3,5-dione was
detected at 0.02-0.5 mg/L in wastewater and 0.001-0.006 mg/L in river water. The
chemical

4-butyl- l,2-diphenyl-3,5-pyrazolidinedione

is

the

structural

name

for

Phenylbutazone, which is used as a non-steroidal anti-inflammatory drug (NSAIDs). The
pharmaceutical 5-(3-Dimethylaminopropyl)- 10,11-dihydrodibenzo [b, f] azepine is a
useful drug that possesses antidepressant properties (Monro et al. 1963). Following the
detection of lipid lowering clofibric acid, antidepressant imipramine (Jungclaus et al.
1978), and a number of other classes of pharmaceuticals (Richardson and Bowron 1985),
the post-therapeutic fate and effects of pharmaceuticals have quickly emerged as an issue
of widespread environmental interest in the last few decades.

Over the last few decades, many studies have shown the presence of emerging
environmental residuals in aquatic environments, their continuous persistence, and their
mounting toxicity, mostly from pesticides and endocrine disrupting compounds (EDCs).
Despite their higher consumption and greater disposal than those of other diverse groups
of bioactive chemicals, these pharmaceuticals receive comparatively less attention as
potential environmental pollutants (Temes 1998, Daughton and Temes 1999, Kolpin et
al. 2002, Heberer 2002b, Richardson 2003, Kümmerer 2004). Pharmaceutical compounds
and their metabolites are collectively referred to as pharmaceutically active compounds
(PhACs) (Daughton and Temes 1999). This large group of pharmaceuticals consists of
2

non-prescription drugs, prescription drugs, veterinary medicines, growth promoters,
diagnostic agents, and dermatology related compounds (Halling-Sorensen et al. 1998,
Barcelo and Petrovic 2007). Although, these compounds have only recently been
recognized as environmental contaminants, they have attracted the attention of the
general public and the scientific community. Concern has been raised about their
continuous release into the environment at low concentrations and the possible subtle
effects of these compounds on non-target organisms over an extended period of time
(Jones et al. 2005a; Barcelo and Petrovic 2007).

However, recently researchers have extended their analysis to a much broader range of
pharmaceuticals as these compounds are being detected on a wider scale worldwide.
Concerns relating to human and ecological health due to environmental contamination
have been reported (Daughton and Temes 1999), particularly when the use of the anti
inflammatory drug, diclofenac (DCF), was found to have catastrophic consequences on
the population of vultures in India and Pakistan (Oaks et al. 2004). Despite the increasing
awareness of the presence of pharmaceuticals, little is still known about their behaviour,
in terms of their fate and effects, after their entry into the environment (Daughton and
Temes 1999).

1.2

Problem Overview

Studies have shown that pharmaceuticals have been identified as emerging environmental
contaminants over decades (Daughton and Temes 1999, Weigel et al. 2004). There are
several potential sources and mechanisms through which these compounds reach the
environment, including wastewater effluents, agricultural runoffs, and septic system bed
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leaching. Consequently, such compounds have been found to be present in surface
waters, ground waters, and treated waters (Kolpin et al. 2002, Stackelberg et al. 2004,
Zuehlke et al. 2004, Sosiak and Hebben 2005). In many cases drinking water standards or
lifetime health advisories do not yet exist for these substances, making it difficult to
assess the need for the removal of these compounds during water treatment. A few
researchers have evaluated the potential risks of exposure to individual pharmaceuticals
at environmental concentrations, including drinking water as an exposure pathway, and
have determined that there is no risk to humans (Webb et al. 2003, Schwab et al. 2005).
On the other hand, it is presently unclear whether there would be increased toxic effects
or synergistic effects through exposure to multiple compounds, even at very low levels
(Stackelberg et al. 2004). A recent study by Pomati et al. (2006) demonstrated that a
mixture of pharmaceuticals at typical environmental concentrations (ng/L range) can lead
to physiological and morphological effects on human embryonic cells. This study
emphasizes the need for further studies to evaluate the long-term risks and to characterize
potential interactions between pharmaceutically active ingredients present in the
environment (Pomati et al. 2006). Though effective analytical technology for these
compounds has recently been developed (Temes 2001, Kolpin et al. 2002), it involves
high costs if used on a routine basis. It is likely that with increased urbanization and
further

degradation

of water

supplies,

contamination

of source waters

with

pharmaceuticals will only increase; therefore, in anticipation of relevant toxicology data,
it is imperative that the water treatment industry moves forward to investigate the
removal of pharmaceuticals for which standards may exist in the future. As public
awareness increases there is likely to be greater pressure on the scientific and engineering
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community and utilities to provide some sort of response - either through relevant
toxicology studies or by taking proven actions to minimize any threats.

Among the common therapeutic targets that included treatments for pain management,
cardiovascular disease, antibiotics and nervous system disorders as classified in Table 2
(see Therapeutic class of pharmaceuticals in chapter 2), drugs that are used to treat pain,
such as the analgesics and NSAIDs, are found to be highly ranked in the list of dispensed
drugs in any country worldwide (Stuer-Lauridson et al. 2000 [Denmark], Jones et al.
2002 [England], Kolpin et al. 2002 [USA], Metcalfe et al. 2003a [Canada], Zuccato et al.
2005 [Italy]). A feature of these NSAIDs drugs used for pain management is that they are
available over the counter and thus their level of exposure to aquatic organisms could be
high, based mainly on their volume of use.

In 2011, health regulators in the U.S. announced they are limiting the amount of
acetaminophen (classified as a NSAIDs) found in prescription painkillers, in an effort to
cut the thousands of cases of liver damage in the United States each year (CTV news,
Canada).

As an attempt to addressing the above issues, the present research sought to reduce the
knowledge gaps in treatment options and analysis of PhACs under selected operational
conditions. The research focused on an investigation of the removal of selected PhACs
using UV/H 2O2 based advanced oxidation process from diverse water matrices. In
Canada, until now very few studies have been conducted on diverse water matrices using
AOPs.
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1.3

Scope and Objectives
1.3.1

Scope

The first part of this research is dedicated to the occurrence and fate of two most common
and widely used drugs consumed worldwide: ibuprofen and naproxen. These acidic drugs
were analyzed in two sewage treatment plant (STP) effluents in southwestern Ontario
over five months. It was considered important to evaluate the contamination of
wastewaters and natural waters by two of the most used anti-inflammatory drugs, prior to
performing experiments on the efficacy of removal of these compounds from different
water matrices.

In this study ibuprofen (IBP) and naproxen (NPX) were chosen because of their large
application quantity in medicine and high concentrations found in aquatic environment in
previous studies, as discussed under the section on selection of target compounds. For
analytical determination and quantification, a sensitive analytical method based on an
enrichment step, chromatographic separation and mass spectrometric determination with
derivatization was followed prior to detection and treatment. Samples of sewage from
STPs located in London, Ontario, were screened for the presence of pharmaceuticals in
water matrices and matrix effects were evaluated during the treatment experiments with
UY/H20 2.

6

1.3.2 Objectives
The specific objectives of the study were to

• Identify and quantify the presence of two target NSAIDs, ibuprofen and naproxen,
in effluent from sewage treatment plants (STPs) in London, Ontario, Canada.
• Evaluate the removal of the target compounds using UV irradiation alone and
UV/H 2O2 AOP under a bench-scale study where low pressure (LP) and medium
pressure (MP) lamps were employed.
• Determine the reaction kinetics (fluence based as well as time based) for direct
and indirect photolysis of each selected compound in three water matrices.
• Assess the feasibility of using UV/H2O2 to remove pharmaceutical compounds in
the presence of matrix interferences, as wastewater may be considered to have a
very complex matrix.

The overall objective was to investigate the degradation of ibuprofen and naproxen in
different water matrices (laboratory grade water, surface water and wastewater) using
UV/H20 2 treatment process and to determine the reaction kinetics for direct and indirect
photolysis of the target compounds in different water matrices for comparison. In
different water matrices, LP fluence and MP fluence variation were also observed for
these analytes.

1.4

Outline of the Thesis

The rest of the thesis is outlined as follows:
7

•

Chapter two presents a review of pertinent literature to highlight several aspects
of research conducted on pharmaceuticals in the aquatic environment, with
respect to their fate, effects, analysis and treatment.

•

Chapter three discusses gas chromatography and mass spectrometry (GC/MS), the
main analytical methods used in the research, focusing on data recovery, method
detection limits, analysis of real water samples, and advantages of the method.

•

Chapter four describes in detail how hydrogen peroxide enhanced UV degradation
of ibuprofen in water treatment works under UV based advanced oxidation
process.

•

Chapter five of the research presents the degradation and removal of naproxen
from treated wastewater using UV and UV based advanced oxidation process.

•

Chapter six presents the summary of the results and draws final conclusions with
recommendations for future research.

Finally, instrumentation parameters, hydrogen peroxide stability data, and water
absorbance spectra for the treatment work performed in the research are presented in the
appendices.

1.5

Selection of Target Compounds

The target compounds were selected after a survey of the literature on the occurrence of
pharmaceuticals in Canadian wastewater, surface water and drinking water. Many
pharmaceutical compounds have regularly been found in Canadian wastewaters, surface
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waters, and drinking water as described by different literature.

Thus, the relevant

literature review is given in Chapter 2.

This work has been focused on two pharmaceutical substances widely consumed
worldwide and not readily biodegradable: ibuprofen and naproxen. They are nonsteroidal
anti-inflammatory drugs (NSAIDs) and possess analgesic and antipyretic activities. They
are used for the relief of symptoms of rheumatoid arthritis and osteoarthritis and appear
to have been used for the relief of mild to moderate pain. They are also identified for the
treatment of primary dysmenorrhea.

The structures and the solubility values of the investigated drugs are found in Chapter 3.
Few studies focus on the removal of the target compounds in Canadian environment,
where these compounds have reported to be persistent (Metcalfe et al. 2003b, Rahman
2008). Moreover, sparse data are available on the removal of these pharmaceuticals in
wastewater. Therefore, the target pharmaceuticals were investigated in both London
Wastewater Treatment Plants and Elgin Drinking Water Treatment Plant within
southwestern Ontario watershed.

1.6

Contribution of the Thesis

This study focuses on ibuprofen and naproxen removal in wastewater using UV/H 2O2
based AOP -as earlier research had found that these compounds are not completely
removed either by conventional wastewater treatment technologies or by other advanced
oxidation processes. Therefore, the findings and the results of this work will provide
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valuable information for water treatment utilities as well as regulatory bodies (for
example, Ministry of Environment (MOE), Ontario) and hence emphasizes the necessity
for the implementation of UV/H 2O2 technology in water treatment plants.

While the analysis of PhACs is highly challenging due to their very low environmental
concentrations (ng/L-pg/L), most reported studies lack comprehensive description and
presentation of treatment and analytical aspects, such as calibration. However, calibration
is important for establishing any analytical approach. Consequently, the analytical
methods used in the present work were validated in terms of calibration, recovery test,
chromatographic separation, identification and detection.

This study is believed to be one of very few investigations into the degradation of
environmentally persistent pharmaceuticals in diverse water matrices (laboratory grade
water, wastewater, source of drinking water) using UV/ H2O2 process for water treatment
facilities in southwestern Ontario, Canada. The treatment experiments were conducted in
bench scale reactors, and therefore the irradiation measurement is less complex than in a
full-scale UV reactor. The findings of the study have implications for wastewater and
drinking water treatment and strongly suggest that the results of the experiments have
implications for wastewater and drinking water treatment facilities.

During the treatment work, water absorbance spectra and H 2O2 concentrations were
measured to evaluate the effect of the different water matrices on treatment. Hydrogen
peroxide (H2O2) stability was also evaluated for the three water matrices, -as it is known
to be unstable in wastewater, a very complex matrix. Moreover, the applied H2O 2 dosage
was similar to values used in full scale application. In the water industry, hydrogen
10

peroxide has wide "application for the treatment of water. The selected and applied UV
dosages showed leading degradation for the target analytes. Since, these compounds
cannot be removed by the use o f H2C>2, alone, UV/H2O 2 may be a better integrated
treatment option in water treatment plants, in particular, wastewater treatment plants
(WWTP), as shown in the present study. Absorbance spectra of the target analytes were
measured to evaluate the photodegradation process.

To the knowledge of the author, the present study is the first attempt to characterize the
WWTP effluent for the City of London, ON. The findings can be used to develop
strategies for regular monitoring of pharmaceutically active compounds and their removal
by enhanced degradation.
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CHAPTER 2
LITERATURE REVIEW

2.1

Introduction

To give an indication of the present state of research on pharmaceuticals in the aquatic
environment, with respect to their fate, this chapter reviews pertinent literature on the
effects, analysis and treatment of these compounds.

2.1.1 Pharm aceuticals in Aquatic Environm ent
Recently, it has been well documented that pharmaceuticals are emerging environmental
contaminants (Halling-Sorensen et al. 1998, Daughton and Temes 1999, Jones et al.
2001, Heberer 2002a, Richardson 2003) detected in a number of environmental matrices,
including wastewater (Temes 1998, Buser et al. 1999, Khan and Ongerth 2002, Metcalfe
et al. 2003a, Ashton et al. 2004, Castiglioni et al. 2005, Castiglioni et al. 2006, Al-Rifai
et al. 2007) to the source o f drinking water (Temes 1998, Stumpf et al. 1999, Heberer
2002a, Kolpin et al. 2002, Boyd et al. 2003, Metcalfe et al. 2003b, Stackelberg et al.
2004, Hao et al. 2006, Hua et al. 2006, Kim et al. 2007). A number of studies are
focusing on wastewater as research has found that these compounds are not completely
removed by conventional wastewater treatment technologies (Golet et al. 2002, Temes et
al. 2003, Kreuzinger et al. 2004, Tauxe-Wuersch et al. 2005, Westerhoff et al. 2005),
which results in a major pathway for these compounds to enter aquatic ecosystems (Miao
et al. 2005, Lishman et al. 2006, Gomez et al. 2007, Kim et al. 2007).
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2.1.2 Usage and Consum ption
With nearly $800 billion in drugs sold worldwide, pharmaceuticals are increasingly being
released into the environment. More than 22,000 pharmaceutical therapeutic products in
Canada make their way from the laboratory to the marketplace (http://www.hc-sc.gc.ca).
Increased usage o f pharmaceuticals world-wide is directly correlated to an increasing
population and increased consumption of pharmaceuticals by individuals (Rabiet et al.
2006). Consequently, pharmaceuticals are continuously being released into the
environment and the contamination of the environment by drugs is poised to worsen as
the global appetite for medications swells.

In Canada, ibuprofen and naproxen along with other pharmaceuticals are active
ingredients in a number of drug products on the market. Naproxen is used predominantly
as a human anti-inflammatory agent and is a commonly prescribed non-steroidal anti
inflammatory drug (NSAIDs) (Bran et al. 2006), whereas ibuprofen is prescribed or can
be purchased without a prescription. Ibuprofen, followed by paracetamol, is present in
high concentrations in wastewaters as both are easily accessible over-the counter
analgesics. These are followed by the highest prescription drags such as lipid regulators
in Australia and Canada (Al-Rifai et al. 2007, IMS Canada, 2009).

Among the ten most dispensed therapeutic pharmaceutical classes in Canada, analgesics
ranked sixth according to 2009 statistics (Appendix A). Ranking drags has the advantage
of estimating which drags are likely to be detected in the aquatic system, due to the
volume of use. According to their statistics analgesics, gastrointestinal and neurological
therapies showed the highest prescription volume growth in 2009.
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Due to relatively few environmental surveys of pharmaceuticals being undertaken,
therapeutic use statistics of medicines has been considered as a useful tool in estimating
the amount of pharmaceuticals that can enter the aquatic environment. The World Health
Organization (WHO) Collaborating Centre for Drug Statistics Methodology has
developed the defined daily dose (DDD) for estimating population drug use.

Table 1: W HO defined daily dose (DDD) for NSAIDs
N S A ID

DDD

P rescrib ed Q u a n tity

T otal Q u a n tity /D D D

D ic lo fe n a c

100m g

5 0 ,0 0 0 m g

5 0 ,0 0 0 /1 0 0 = 5 00

Ib u p ro fe n

1200m g

2 1 6 ,0 0 0 m g

2 1 6 ,0 0 0 /1 ,2 0 0 = 1 8 0

N a p ro x e n

500m g

4 ,8 0 0 m g

4 ,8 0 0 /5 0 0 = 9 .6

In d o m e th a c in

1 0 0m g

2 ,0 0 0 m g

2 ,0 0 0 /1 0 0 = 2 0

M e fe n a m ic ac id

1,0 0 0 m g

1 0 ,000m g

1 0 ,0 0 0 /1 ,0 0 0 = 1 0

Source: British National Formulary

E tti r^oestradid
Irxtornethadn
Gerrfi brazil
Diclofenac

A rovastatin
CarbamazBpine
N apraen

Ixprofen
Acetylsalicydic ad d
ADetorrirophen
10
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1000

10000

Canacfian sales(kg)

Figure 1 : Therapeutic Pharm aceuticals Sales in Canada
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Figure 1 illustrates the sales pattern (kg) in 2001 for a range of pharmaceuticals in
Canada (adapted from Kümmerer 2004).

2.1.3 Pathways o f Pharm aceutical Compounds into the Aquatic
Environm ent
The ubiquitous presence of pharmaceuticals in the environment with their worrying levels
of reporting to-date in North America and Europe has stimulated interest in
understanding the sources and pathways by which these compounds enter the
environment. Reviews by Halling-Sorensen et al. (1998), Temes (1998), Heberer (2002b)
and Derksen et al. (2004) have illustrated possible exposure routes for the entry of human
and veterinary pharmaceuticals into the environment. Conventionally, environmental
concerns stemmed from contamination at point sources such as industrial processes,
manufacturing and waste disposal sites.

Human pharmaceuticals enter the environment mainly through their therapeutic use. The
drug is excreted via urine or feces as various combinations of metabolites, the parent
compound or conjugated compounds (Halling-Sorensen et al. 1998). Typically, active
pharmaceutical ingredients are metabolised to form more polar and water soluble forms
via phase I reactions such as oxidation, reduction and hydrolysis. These may be followed
by phase II reactions which are generally conjugation reactions (Kümmerer 2004). The
major route (Figure 2) by which human pharmaceuticals and their metabolites enter the
aquatic environment is through the discharging of these compounds into surface waters
from domestic waste after incomplete removal during wastewater treatment (Temes
1998, Heberer et al. 2002, Metcalfe et al. 2003b, Lishman et al. 2006). The release of
veterinary pharmaceuticals into the environment can take place directly when the
15

livestock animals are on pasture or indirectly by run-off or leaching through the soil
(Derksen et al. 2004). Surface runoff and leaching after the application of manure
depends on a number of parameters, including climatological conditions as well as the
physical and chemical properties of the compound (Derksen et a l 2004).

Figure 2: Possible Pathways of Pharmaceuticals in the Environment. (Adapted from
Petrovic et al. 2003).
In either case, for human and veterinary pharmaceuticals, these compounds will
eventually enter surface waters or infiltrate into groundwater aquifers, which can be used
for potable water use (Jones et al. 2001). The concern with drinking water supplies
contaminated with pharmaceuticals will continue to grow as urbanization and
intensification

of

animal

production

increases.
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Improper

disposal

of unused

pharmaceutical contributions to the loading of PhACs into the environment should not be
ignored.

2.1.4 Occurrence in the Aquatic Environm ent
In recent years, the occurrence and fate of PhACs in the aquatic environment is
recognized as one of the emerging issues in environmental chemistry and a matter of
public concern. Residues of PhACs have been found as contaminants in several
investigations of sewage, surface, and ground water samples (Daughton and Temes
1999). Due to the high amounts of pharmaceuticals prescribed in human medical care,
considerable amounts of persistent drug residues are passed through the municipal
sewage plants which therefore act as point sources for the neighbouring waters. Thus,
drug residues are found at concentrations up to the pg/L level in surface waters
contaminated by municipal sewage effluents.

Pharmaceutical contamination of aquatic systems is an emerging issue in environmental
science and engineering. The presence of pharmaceuticals in raw and treated wastewater
has been well documented with concentrations averaging from less than 10 pg/L in
treated wastewater to greater than 100 pg/L in raw wastewater (Temes 1998, Buser et al.
1999, Jones et al. 2001, Heberer 2002b, Lindqvist et al. 2002, Boyd et al. 2003, Lee et al.
2003, Metcalfe et al. 2003a, Petrovic et al. 2003, Tixier et al. 2003, Carballa et al. 2004,
Thomas and Foster 2004, Castiglioni et al. 2005, Quintana et al. 2005, Vieno et al. 2005,
Brun et al. 2006, Ellis 2006, Gros et al. 2006, Zuccato et al. 2006, Gomez et al. 2007,
Radjenovic et al. 2007). Pharmaceuticals that have been detected in effluent and rivers
include analgesics, antiepileptics, antibiotics, (3-blockers, blood lipid regulators, contrast
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media, and oral contraceptives. Table 2 shows a list of classification of pharmaceuticals
compounds.

Surveys of WWTP influents and effluents have concluded that the main therapeutic
classes detected are P-blockers, analgesics, anti-epileptics and lipid regulators. For
example, Santos et al. (2007) detected ibuprofen in wastewater influent and effluent at
concentrations of 12.1 - 373 and 0.78 - 48.2 pg/L, respectively. Naproxen was also
detected at 1.1 - 27.4 pg/L in wastewater influent and 0.22 - 4 .3 pg/L in effluent. Gomez
et al. (2007) detected acetaminophen, codeine, diclofenac, and ibuprofen in wastewater
influent at mean concentrations of 134, 5.2, 1.5, and 84 pg/L, and in wastewater effluent
at mean concentrations of 0.22, 3.7, 0.9, and 7.1 pg/L, respectively. A survey of the
occurrence of pharmaceuticals in US streams showed that the pharmaceuticals ibuprofen,
fluoxetine and triclosan, were present at low concentrations (ng/L range) in WWTP
effluents but were not detected in surface waters (Boyd et al. 2003). However, other
studies demonstrated that some pharmaceuticals are ubiquitous and can be detected in the
receiving waters. In the UK, pharmaceuticals were detected in estuaries at concentrations
up to 111 ng/L for clofibric acid, 125 ng/L for diclofenac and 928 ng/L for ibuprofen
(Thomas and Hilton 2004). Kasprzyk-Hordem et al. (2008) found more than 50
pharmaceuticals, EDCs and illicit drugs in UK surface waters, where the anti
inflammatory compounds codeine (up to 813 ng/L), naproxen (up to 146 ng/L),
ketoprofen (up to 14 ng/L ibuprofen (up to 93 ng/L and diclofenac (up to 261 ng/L) were
amongst the most frequently detected. Rabiet et al. (2006) identified acetaminophen,
carbamazepine, and diclofenac in surface water at concentrations of 0.011 - 0.072, 0.024
- 0.056, and 0.001 -0.033 pg/L, respectively.
18

Table 2: List of some chemicals classified as pharmaceutical groups (Snyder et al. 2003, Esplugas et al. 2007)
Therapeutic Use

Pharmaceuticals class

Compound detected

Antibiotics

Antibiotics/antimicrobials

Sulfonamides, fluoroquinolones, trimetoprim,
Chlortetracycline, erythromycin, lincomycin,
Oxytetracycline, tetracycline, roxithromycin,
tylosin

Analgesic/Antipyretics

Analgesic, antipyretic

Acetaminophen

Nonsteroidal anti-inflammatory

Diclofenac, naproxen, ibuprofen, ketoprofen
Carbamazepine

drugs (NSAIDs)
CNS (Central nervous system) drugs

Antiepileptics

Caffeine

CNS stimulant
Beta blockers

Propranolol, atenolol, metoprolol

Cholesterol and Triglyceride reducers

clofibric acid, gemfibrozil, fezafibrate

Endocrinology treatments

Steroid hormones. Contraceptives

17a-ethinylestradiol, estrone, 17ß-estradiol,
estriol

Diagnostic aid-adsorbable organic

X-ray contrast agents

Diatrizoate, iopamidol, iopromide, iomepol

Cardiovascular drugs

halogen compounds

2.1.4.1 The Presence of Pharmaceuticals in the Aquatic Environment: Canadian
Perspective
In Ontario, Canada, ibuprofen was detected at a concentration 17.2 ng/L in the raw water
sample where the samples were collected from Lake Huron (Rahman 2008). Ibuprofen is
degraded in the human body to its principal metabolites hydroxy- and carboxy-ibuprofen
and to carboxy-hydratropic acid which are found together with ibuprofen in raw sewage
(Heberer 2002a). Among other analgesics naproxen has also been detected in sewage and
surface water samples.

Sewage: Table 3 lists the concentrations of PhACs detected in treated effluent samples
collected from Canadian sewage treatment plants (STPs) in 1999-2002 (Kummerer
2004). The occurrence of these PhACs was investigated in the treated effluent samples
from eighteen STPs in fourteen municipalities in Canada (Metcalfe et al. 2003a). The
concentrations of the acidic PhACs in the treated effluents were also reported from two
STPs in Whitby, Ontario (Miao et al. 2002), and in the effluents from four STPs for the
cities of Peterborough, Burlington, Hamilton and Windsor, Ontario (Lee et al. 2003,
Metcalfe et al. 2003b, Hua et al. 2006). The maximum concentrations of the anti
inflammatory drugs ibuprofen and naproxen in the treated effluents of STPs in Canada
during that period were observed greater than the maximum concentrations reported for
STP effluents in Germany, Switzerland or South Korea (Temes 1998, 0"llers et al. 2001,
Kim et al. 2007).
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Table 3 : Concentrations of acidic PhACs in treated effluent samples collected
from Canadian STPs during 1999-2002 (pg/L) as reported by Lee et a l (2003),
Metcalfe et al. (2003a,b), Miao e t al. (2002), and Hua et a l (2006)
Analyte

Maximum concentration reported (pg/L)

Naproxen

33.90

Bezafibrate

0.60

Clofibric acid

0.044

Diclofenac

0.359

Fenoprofen

0.405

Gemfibrozil

2.174

Ibuprofen

24.60

Indomethacin

0.378

Ketoprofen

0.013

Lovastatin

0.014

Atrovastatin

0.044

Pravastatin

0.059

Salicylic acid

59.60

Surface water: Table 4 lists the concentrations of acidic PhACs that have been reported
in surface water in Canada in a number of studies. These data include surface water
samples collected in the region of the Detroit River, Hamilton Harbour and Lake Ontario
during the sampling period 1999-2002 (Boyd et al. 2003, Metcalfe et al. 2003b, Hua et
al. 2006). The reported concentrations of ibuprofen and naproxen in these water samples
exceeded the maximum concentrations previously reported in Switzerland (0"llers et al.
2001).
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Table 4 : Concentrations of acidic PhACs in surface waters adjacent to discharges
of effluents from sewage treatment plant effluents during 1999-2002 (pg/L) as
reported by Boyd et al. (2003), Metcalfe et al. (2003b), and Hua et al. (2006)
Analyte

Maximum concentration reported (pg/L)

Naproxen

0.551

Bezafibrate

0.137

Clofibric acid

0.175

Diclofenac

0.194

Fenoprofen

0.142

Gemfibrozil

0.112

Ibuprofen

0.790

Indomethacin

0.018

Ketoprofen

0.047

Lovastatin

n.d

Atrovastatin

0.015

Pravastatin

n.d

Salicylic acid
n.d=not detected

-

Drinking Water: In a study, Servos et al. (2007) investigated the presence of few PhACs
and the antimicrobial substance triclosan, in raw water and finished water of twenty
drinking water plants across southern Ontario. None of the raw or finished water samples
taken from wells showed detectable levels of any of the PhACs. River water samples
downstream o f sewage effluent outfalls showed the highest level of contamination with
ibuprofen and naproxen. Ibuprofen was the only drug found in finished drinking water
from River water source at detectable level (Servos et al. 2007).
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Table 5 : Concentrations of acidic PhACs in raw and finished drinking water (ng/L)
in Ontario, Canada separated according to the source of the water (Servos et al.
2007).
Analytes

Raw water

Finished water

Wells

Lakes

Rivers

Wells

Lakes

Rivers

n.d

0.5

0.7

n.d

0.2

0.4

Ibuprofen

n.d

2.5

75

n.d

2.0

55

Gemfibrozil

n.d

4.0

8.0

n.d

0.7

n.d

Fenoprofen

n.d

n.d

5.5

n.d

n.d

n.d

Naproxen

n.d

6.0

70

n.d

n.d

1.5

Ketoprofen

n.d

n.d

n.d

n.d

n.d

n.d

Diclofenac

n.d

n.d

8.0

n.d

n.d

n.d

Indomethacin

n.d

n.d

2.5

n.d

n.d

n.d

Clofibric
acid

n.d=not detected

2.1.5 Environm ental Fate
Organic contaminants present in municipal wastewater, such as pharmaceuticals, may be
removed or transformed by a variety of mechanisms. In conventional STPs,
pharmaceuticals can be removed by sorption to particles or by biotransformation (Sedlak
and Pinkston 2001). Sorption of pharmaceuticals via other interactions usually requires
the presence of acidic, phenolic, or amino functional groups. Although many of the
pharmaceuticals contain such functional groups, removal via these mechanisms is not
expected to be significant under the conditions encountered in municipal wastewater
(Sedlak and Pinkston 2001).
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2.1.6 Human Exposure to Pharmaceuticals
Indirect human exposure to PhACs via drinking water is becoming a serious concern. It is
possible that humans could be exposed to mixtures of drugs in drinking water that could
result in unpredicted subtle health effects as a consequence of chronic, low-level
exposure to these types of compounds. Pharmaceuticals that target specific receptors may
have effects on non-target organisms at very low concentrations. Although, these
substances are usually found in very low concentrations in the environment, continuous
low dose exposure could pose chronic effects. As for example, little is known about the
effects of transplacental exposure of the fetus in pregnant women indirectly exposed to
drugs in drinking water (Webb et al. 2003).

2.1.7 Environm ental R isk Assessment
Trace amounts of pharmaceuticals have been detected in sewage treatment plant (STP)
influents, effluents, surface waters, groundwater and drinking waters. For some
pharmaceuticals -effects on aquatic organisms have been investigated in acute toxicity
assays. Pharmaceuticals are continuously released in the environment and aquatic
populations are exposed to low concentrations of pharmaceuticals throughout their life
which may affect their development, reproduction or survival rate. Jones et al. (2005a)
and Webb et al. (2003) have compiled the acute toxic effects of pharmaceuticals
including diclofenac, naproxen, ibuprofen and ketoprofen. In this regard, the study of
environmental risk assessment of pharmaceuticals by Bound et al. (2006), Fent et al.
(2006), Cooper et al. (2008) is worthy of mention. These studies suggest that severe
effects from exposure to relatively low levels of some pharmaceuticals are possible, as
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shown by the recent discovery that vultures in Asia have been dying from eating cattle
containing relatively low concentrations of the drug diclofenac (Oaks et al. 2004).

2.1.8 R egulatory Fram ework
The issue of PhACs in the environment has a high profile in Canada because o f recent
studies suggesting widespread distribution in the environment, including drinking water
(Servos et al. 2007). Regardless, there are currently no specific regulatory guidelines for
the risk posed by the presence of trace concentrations o f PhACs in drinking water in
Canada, or in any countries.

2.2

Environmental Analysis of Pharmaceuticals

Recent improvements in analytical techniques have expanded the area for learning the
occurrence, fate and transport of organic pharmaceuticals and many other pollutants in
the aquatic environment. Due to the low concentration (ng/L to pg/L) of pharmaceuticals
found in the environment, sample concentration and clean-up steps are usually required
prior to analysis to meet these requirements. Therefore the success of the analysis relies
on the quality of the extraction. Several techniques exist for sample preparation such as
pressurised liquid extraction, ultrasonic solvent extraction, stir bar sorptive extraction and
more recently on-line solid phase extraction, liquid phase microextraction and solid phase
microextraction, where liquid-liquid extraction (LLE) and solid phase extraction (SPE)
are the most common techniques used to separate and concentrate pharmaceuticals from
environmental aqueous matrices (Ridgway et al. 2007). The subsequent analysis is

25

typically performed using gas or liquid chromatography (GC and LC, respectively)
combined with mass spectrometry (MS).

Advancements made in this area of environmental chemistry have allowed researchers to
determine the occurrence of pharmaceuticals in the environment and apply this
information to help assess the impacts of these compounds on environmental and human
health.

2.3

Pharmaceuticals Removal in the Aquatic Environment

The traditional methods used for water treatment such as adsorption on activated carbon,
flocculation and filtration are inefficient to degrade most of the organic compounds, such
as pharmaceuticals and hence for their complete removal from water. Most of these
compounds are found to be resistant to biodegradation. Recently, research is being
focused on the development of new technologies for the safe destruction of micro
pollutants. The use of advanced oxidation processes (AOPs) to remove pollutants in
various water treatment applications has been the subject of study for nearly 30 years
(Suty et al. 2004). Advanced oxidation processes (AOPs) have been used for the
treatment of wastewater containing recalcitrant organic compounds such as pesticides,
surfactants, colouring matters, pharmaceuticals and endocrine disrupting chemicals. In
the near future, AOPs may become the most widely used water treatment technologies for
refractory, toxic and organic pollutants that are not treatable by conventional technologies
due to the high chemical stability or low biodegradability of such pollutants.
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2.3.1 A dvanced O xidation Process (AOP)
Advanced oxidation processes (AOPs) are chemical oxidation techniques able to produce
in situ reactive free radicals, mainly the hydroxyl radical (*OH), by means of different
reacting systems. The concept was originally established by Glaze et a\. (1987) as
“Oxidation processes which generate hydroxyl radical in sufficient quantity to affect
water treatment”. The commonly used Advanced Oxidation Processes include
photodissociation of hydrogen peroxide (H2O2/UV), photolysis of ozone (O 3/UV), Fenton
reaction (Fe2+/ H2O2), Photo-Fenton reaction (Fe2+/ H2O 2/UV), photocatalysis (Ti0 2 /TJV)
etc. Each method has its own merits and limitations, and the efficiency of each process
depends on the ease with which it can be operated, the cost effectiveness, the extent of
mineralization achieved and finally the reaction time. Most of these methods are effective
in bringing about the complete oxidation of organic pollutants, thus achieving the lowest
level of pollution.

The main mechanism of AOPs function is the generation of highly reactive free radicals.
•OH is a non selective oxidant that is able to oxidize a wide range of organic molecules
with rate constants usually in the order of 106-109 M ' 1 s’ 1 (Andreozzi et al. 1999). Table 6
lists the oxidation potential of several oxidative species commonly used in water and
wastewater treatment. The »OH radical is among the strongest oxidizing species used in
water and wastewater treatment and offers the potential to greatly accelerate the rates of
contaminant oxidation (Zhou and Smith 2001). Once generated, the hydroxyl radicals can
attack organic chemicals by radical addition, hydrogen abstraction and electron transfer.
The reaction of hydroxyl radical with organic pollutants can lead to complete
mineralization to produce CO2 and, H2O.
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Table 6 : Free *OH radical
Species

Oxidation potential

Fluorine

3.03

Hydroxyl radical

2.80

Atomic Oxygen

2.42

Ozone

2.07

Hydrogen peroxide

1.78

Perhydroxyl radical

1.70

Permagnate

1.6 8

Hypobromous acid

1.59

Chlorine dioxide

1.57

Hypochlorous acid

1.49

When treating wastewater, it must be considered that besides organic matter in solution,
inorganic ions are also present. These inorganic species can be initially contained in the
wastewater as well as can be produced during the mineralization of organic pollutants.
Therefore, these inorganic species must be considered because if they occur at relatively
high concentration, they can inhibit pollutant destruction or abatement (Andreozzi et al.
1999). As well, natural organic matter (NOM) in solution, such as humic acids, may also
act as hydroxyl radical scavengers. Table 7 presents the classification of some AOPs as
photochemical and non-photochemical processes basis.
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Table 7 : Classification of some AOPs as photochemical and non-photochemical
processes
Non-photochemical processes

Photochemical processes

Ozonation in basic m edia(0 3 /*0H)

O3 /UV (X. < 320 nm)

O 3 /H 2 O2

H2 0 2/UV (X, < 300 nm)

O3 / Ultrasound

0 3/ H2 0 2/UV (1 < 320 nm)

H2 0 2/Ultrasound

Photocatalytic ozonation

Fenton (Fe2+/ H2 0 2)

Heterogeneous photocatalysis (T i0 2 /UV) (X, < 400 nm)

Electro-Fenton

Photo-Fenton (Fe2+/ H 2 0 2 /UV)

(k <

320 nm)

(k

< 550 nm)

2.3.2 Advantages and Disadvantages o f Different AOPs

Description of the Various AOPs:
a) Photo-Fenton Process: Photo-Fenton process involves the reaction of ferrous ions
(catalyst) and hydrogen peroxide (oxidizing agent) under UV/Visible radiation to form
active oxidant species, mainly hydroxyl radical, which oxidize organic compounds when
they are present in aqueous solution.

b) Heterogeneous Photocatalysis: Heterogeneous photocatalytic processes use certain
metal oxides that can readily generate hydroxyl radicals on the surface of particles when
absorbing UV light. The most important heterogeneous photocatalytic processes include
T i02/UV and T i0 2/ H 20 2/UV (Zhou and Smith 2001).

c) O 3/UV Process: The O3/UV process starts with activating the ozone molecule by UV
to form oxygen radicals, which then combine with water to form -OH radicals.
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0 3+ hv -> 0 2 + 0 (lD )

0(1D) + H20 -> 2 0H

d) Ti02-Photocatalysis/Ozone Process: The TiCh-photocatalysis combined with ozone
can increase the rate of mineralization due to the increment of hydroxyl radicals
production.

e) Hydrogen Peroxide/UV Light Process: H 2O2 is photolyzed under UV irradiation to
form two hydroxyl radicals. The formed hydroxyl radicals then react with organic
contaminants or undergo an H2O 2 decomposition-formation cycle.

H20 2+ hv

2 OH

H20 2+ OH -> H2O + HO2

H 0 2 + H 0 2^

H2O2 + O2

f) O3/ H20 2 Process: H 2O2 reacts very slowly with the ozone molecule in water and it
initiates the formation of hydroxyl radicals in two steps as follows

H20 2 +H20 -> H 0 2 +H30

HO2 + O3

*OH + 0 2 + 02

The rate constant between H 0 2 “ and O 3 is greater as compared with the same between
the OH ion and O3, which yields the effectiveness of H 0 2 ~ ions even at a very low
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concentration for initiating ozone decomposition and facilitating hydroxyl radicals
formation. (Zhou and Smith 2001)
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Table 8 : Advantages & disadvantages of different Advanced Oxidation Processes
Advanced

Process advantages

Process disadvantages

Process applications

Oxidation

Factors to be
considered

Processes
a.

Photo-Fenton

1 .C o m p a re d to o th e r o x id a n ts, h y d ro g e n

T h e m o st d ra w b a c k o f th e p h o to -F e n to n

A m o n g th e m a in a p p lic a tio n s o f

T h e m a jo r p a ra m e te rs

process

p e ro x id e is n o t e x p e n siv e , n o t d a n g e ro u s,

p ro c e s s is th e n e c e s s ity o f p H ad ju stm e n t.

th is d e g ra d a tio n sy stem , th e

a ffe c tin g F e n to n p ro c e s s

a n d e a sy to h a n d le a n d p o se n o la s tin g

W h e n p H in c re a se s m o re th a n 2 .5 -3 .5 ,

tre a tm e n t o f w a ste stre a m s fro m

a re so lu tio n ’s p H , a m o u n t

e n v iro n m e n ta l th re a t sin c e it re a d ily

d e p e n d in g on th e iro n c o n c e n tra tio n a n d

d y e m a n u fa c tu re a n d p a p e r-p u lp

o f fe rro u s ions,

d e c o m p o s e s to w a te r a n d o x y g en .

te m p e ra tu re , th e ferric io n p re c ip ita te s a n d

b le a c h in g e fflu e n ts h a v e b e e n

c o n c e n tra tio n o f H 20 2,

c o u ld fo rm slu d g e th a t p ro d u c e s

w id e ly stu d ie d . B e sid e s, th e

in itia l c o n c e n tra tio n o f th e

te c h n o lo g ic a l tro u b le s. F o r th is re a s o n th e

e lim in a tio n o f to x ic a n d n o n -

p o llu ta n t a n d p re s e n c e o f

o p tim u m p H fo r th e F e n to n p ro c e s s has

b io d e g ra d a b le h e rb ic id e s h a s b e e n

o th e r io n s T h e o p tim u m p H

b e e n d e te rm in e d as slig h tly b e lo w 3.

e ffe c tiv e ly c o n sid e re d b y th is

fo r F e n to n ’s re a g e n t

(A n d re o z z i e t a l. 1 9 9 9 )

m e th o d .

p ro c e s se s ra n g e s fro m 2 to

2. Iro n is a lso re a s o n a b ly p ric e d , safe a n d
e n v iro n m e n ta lly frie n d ly . (P ig n e te llo
2006)

3. S u c h a n e a sy a n d e c o n o m ic a l m o d e to
g e n e ra te h y d ro x y l ra d ic a ls h a s p ro m o te d
th is o x id a tio n m e th o d fo r w a s te w a te r
tre a tm e n t. 4. Im p o rta n t a d v a n ta g e o f th e
p h o to -F e n to n p ro c e s s is th e in e x iste n c e o f
m a s s tra n sfe r lim ita tio n s d u e to its
h o m o g e n e o u s c a ta ly tic n a tu re . 5. P h o to F e n to n p ro c e s s g iv e s fa ste r ra te s a n d a
h ig h e r d e g re e o f m in e ra liz a tio n th a n th e
F e n to n reactio n .

4 .( A n d re o z z i e t al. 1999)

b. Heterogeneous
photocatalysis

1. A d d itio n a l ra d ic a l in itia to rs su c h as

T h e m a in d ra w b a c k a sso c ia te d to th is

H e te ro g e n e o u s p h o to c a ta ly tic

T h e p H in flu e n c e s th e

H 20 2 a re n o t req u ired ,

p ro c e s s is th e lo w q u a n tu m y ie ld s o f lig h t

p ro c e s se s a re a n e m e rg in g

su rfa c e p ro p e rtie s o f th e

a d so rp tio n a n d th e lo w e ffic ie n c y w h e n

te c h n o lo g y . T h e ir a p p lic a tio n s in

se m ic o n d u c to r. T h e m a jo r

c o m p a rin g w ith o th e r A O P s.

o x id iz in g re fra c to ry o rg a n ic

fa c to rs a ffe c tin g T i 0 2/U V

c o n ta m in a n ts still re m a in m o s tly

lig h t p ro c e s s are: in itia l

a t th e la b o ra to ry scale.

o rg a n ic lo ad , a m o u n t o f

2. T h e p h o to c a ta ly s ts m a y b e re u se d ,

3. N a tu ra l ra d ia tio n m a y b e u s e d as a
lig h t so u rc e to a c tiv a te c a ta ly sts,

4 . A m o n g th e d iffe re n t se m ic o n d u c to rs
T i 0 2 is th e m o s t sta b le , e ffic ie n t a n d

A g a in , th e s e c o n d a ry o p e ra tio n s re q u ire d
filtra tio n o r c o a g u la tio n w h e n re c o v e rin g

c a ta ly st, re a c to r’s d e sig n ,

th e c a ta ly st a fte r u se . So th is is a n o th e r

U V irra d ia tio n tim e,

d ra w b a c k o f th is m e th o d .

te m p e ra tu re , s o lu tio n ’s p H ,

p ro m is in g m a te ria l. B e sid e s T i 0 2 is n o n

lig h t in te n sity a n d p re s e n c e

to x ic.

o f io n ic sp ecies.

5. L a rg e n u m b e r o f o rg a n ic c o m p o u n d s in
a q u e o u s so lu tio n s c a n b e d e g ra d e d
c o m p le te ly ,

6 . R a te o f re a c tio n d ire c tly p ro p o rtio n a l

co
co

to su rfa c e o f c a ta ly st

c. O3/UV process:

1. H ig h e r a b so rp tio n c ro s s-se c tio n th a n at

1 .03 does no t absorb light at > 300 nm

T h e O 3/U V p ro c e s s h a s b e e n u se d

2 5 4 nm .

w avelength

in w a te r tre a tm e n t to o x id iz e

2 . D e stru c tio n o f to x ic a n d re fra c to ry

2.

o rg a n ic s a n d m ic ro b ia l p o p u la tio n s.

3. D e c o lo riz a tio n o f b le a c h in g w a te rs.

a lip h a tic a n d a ro m a tic c h lo rin a te d
Low - pressure m ercu ry lam ps em itting short
o rg a n ic c o n ta m in a n ts, p e stic id e s
U V radiation (U V -C ) required
a n d N O M . (Z h o u an d S m ith
3.

L ow O zone solubility in w ater

4.

Potential secondary reactions o f the

2 0 0 1 ).T h is p ro c e s s h a s w id e
a p p lic a tio n fo r g ro u n d w a te r

4 . H ig h e r ra te s o f d e g ra d a tio n th a n U V or
O z o n e u s e d alo n e

oxidative interm ediates
5. T he O 3/U V p rocess is now considered less

tre a tm e n t.

econom ical and less favorable com pared w ith
the 03/H 20 2 and H 20 2/U V processes in m ost
cases.

d . T iO r

T h e se te c h n o lo g ie s h a v e d isa d v a n ta g e s

p h o to c a ta ly s is /o z o n e

re la te d to th e h ig h o p e ra tio n a l costs.

p ro c e s s :

00

-P*

e. H y d r o g e n p e ro x id e /U V

1. T h e H 20 2- U V p ro c e s s h a s a d istin c t

T h e re is an o p tim u m c o n c e n tra tio n for

T h e H 20 2/U V p ro c e s s is m a in ly

T h e m a jo r fa c to rs a ffe c tin g

li g h t p ro c e s s :

a d v a n ta g e b e c a u se o f its s im p lic ity a n d it

H 20 2. B e y o n d th is lim it, th e p re s e n c e o f

u s e d fo r th e o x id a tio n o f

th is p ro c e s s a re th e in itia l

is a n e m e rg in g te c h n o lo g y .

H 20 2 is d e trim e n ta l to th e d e g ra d a tio n

re fra c to ry co n ta m in a n ts.

c o n c e n tra tio n o f th e ta rg e t
c o m p o u n d , th e a m o u n t o f

re a c tio n d u e to sc a v e n g in g a ctio n .
2. T h e o re tic a lly in U V / H 20 2 p ro c e s s, th e

It h a s b e e n u s e d fo r th e

h ig h e r in itia l h y d ro g e n p e ro x id e

d e g ra d a tio n o f p h e n o lic

c o n c e n tra tio n

c o m p o u n d s th a t a re d e te c te d in

p ro d u c e s h ig h e r

h y d ro x y l ra d ic a l c o n c e n tra tio n , w h ic h

o liv e m ill w a ste w a te r a n d a ls o fo r

d e c o m p o s e s m o re ta rg e t c o m p o u n d .

d y e s rem o v al.

H o w e v e r, a n o p tim a l h y d ro g e n p e ro x id e
c o n c e n tra tio n e x ists b e c a u se o v e rd o s in g
o f h y d ro g e n p e ro x id e w o u ld le a d to
re a c tio n w ith h y d ro x y l ra d ic a l a n d
fo rm a tio n o f H 0 2*,w hich h a s le ss
o x id a tio n p o te n tia l.

3 . U V / H 20 2 p ro c e s s is e ffic ie n t in

H 20 2 u se d , in te n sity o f
U V -lig h t, U V d o ses,
w a s te w a te r p H , a n d
re a c tio n tim e.

mineralizing organic pollutants.
4. T h e H 20 2/U V p ro c e s s is w e ll su ite d to
all sy ste m s th a t re q u ire m in im u m
m a in te n a n c e , in te rm itte n t o p e ra tio n , o r
b o th .

5. O n e d is tin c t a d v a n ta g e is, n o
d is in fe c tio n b y p ro d u c t is fo rm ed .

f. 0 3/H20 2 process

The 0 3/H20 2process has used widely

T h e m a jo r d ra w b a c k o f th is p ro c e s s is th e

D u g u e t e t a l [1 9 8 5 ] re p o rte d th a t

b e c a u se o f th e e ffe c tiv e n e ss a n d lo w

fo rm a tio n o f d is in fe c tio n b y p ro d u ts like

e ffic ie n c y o f c o lo r re m o v a l b y

ra d ic a l g e n e ra tio n costs.

n e w trih a lo m e th a n e s fo rm in g p re c u rso rs

o z o n e is a c c e le ra te d b y h y d ro g e n

fro m th e b re a k d o w n o f b ro m a te s (G la z e et

p e ro x id e . T h e lim ita tio n h e re is to

H ig h y ie ld o f O H ra d ic a ls in O 3/ H 2O 2

al. 1987). O z o n a tio n m a y p ro d u c e b ro m a te

m a in ta in th e o p tim u m H 2O 2 to

p ro c e s s m a k e s it m o re a m e n a b le to

w h e n it is a p p lie d to w a te rs th a t c o n ta in

0 3 ratio.

a d a p ta tio n in e x is tin g w a te r tre a tm e n t

b ro m id e .

p la n t. ( G la z e e t al. 1987)
A n o th e r d ra w b a c k is 0 3 is u n s ta b le a n d
c a n n o t b e sto re d as it m u s t b e g e n e ra te d o n
site (G la z e e t al. 1987).

2.3.3 Advanced O xidation Process & Rem oval of
Pharmaceuticals
AOPs can be broadly defined as aqueous phase oxidation methods based on the
intermediacy of highly reactive species such as (primarily but not exclusively) hydroxyl
radicals in the mechanisms leading to the destruction of the target pollutant. Over the past
30 years, research and development concerning AOPs has been immense particularly for
two reasons, namely (a) the diversity of technologies involved and (b) the areas of
potential application (Esplugas et al. 2007). Although water and wastewater treatment is
by far the most common area for research and development, AOPs have also found
applications as diverse as groundwater treatment, soil remediation, municipal wastewater
sludge conditioning, production of ultrapure water and volatile organic compounds
treatment and odor control. (Andreozzi et al. 1999).

The presence of residual pharmaceuticals in the environment and in aquatic systems in
particular constitutes a serious environmental problem as these compounds (a) are
extremely resistant to biological degradation processes and usually escape intact from
conventional treatment plants, (b) may impose serious toxic and other effects to humans
and other living organisms, and (c) are present at minute concentrations, thus requiring
more sophisticated and laborious analytical tools for their accurate determination.

Obviously, the applications of AOPs for water and wastewater treatment are versatile.
Rahman (2008) conducted pre-coagulation O3/ H 2O2 based AOP where it was found that
among nine target compounds, ibuprofen and atrazine were the most recalcitrant to the
system. Again in ozone based AOP, bromate which does not undergo degradation in
biological filters, is the only byproduct of ozonation regulated in drinking water
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treatment. While researchers have demonstrated that bench-scale UV/ TiC>2 systems can
remove pharmaceuticals from water, a major limitation to scaling up this technology has
been the difficulty in separating the Ti0 2 following treatment. Doll and Frimmel (2005)
showed that a microfiltration membrane can be employed to separate TiC^ from water
allowing the technology to be utilized in a flow-through system. Benotti et al. (2009)
presented a technology referred to as a “photcatalytic reactor membrane pilot’’(a patent
process) which employed treatment of pharmaceuticals and EDCs by UV/ Ti0 2
photocatalysis as well as filtration and recycling of the photocatalyst by a ceramic
microfiltration membrane.

Mendez-Arriaga et al. (2008) evaluated and compared the degradation achieved for three
nonsteroidal anti-inflammatory drugs (NSAIDs) by heterogeneous Ti0 2 photocatalytic
means in aqueous solution at laboratory scale. No significant differences were observed
for diclofenac (DCF) and ibuprofen (IBP). This degradation by photolysis has an
important influence on DCF and NPX degradation due to their absorption spectra, which
overleap on the Xe-lamp emission spectrum, specifically above 290nm (in Figure 3).
Packer et al. (2003) cited similar UV-visible spectrum to explain photolability of
naproxen and diclofenac.
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Figure 3: Absorption spectra of DCF, NPX and IBP in Millipore H20 and emission
spectrum of Xe lamp

2.4

Summary

The occurrence and fate of pharmaceuticals in the environment, and in aquatic media in
particular, have received considerable attention by the scientific community during the
last decades. Pharmaceuticals, which are designed to be biologically active substances,
are usually lipophilic and resistant to biodegradation, thus having the potential for
accumulation and persistence in the environment. Although they appear at relatively low
concentrations ranging between ng/L and pg/L levels, they may impose serious effects on
the environment. In the search for suitable technologies to destroy this type of
xenobiotics, AOPs have recently been assessed for their treatment efficiency in the
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presence of several different matrices (surface water, wastewater treatment effluent, etc).
Despite their many advantages, AOPs still have a number of drawbacks. Treatment of
pharmaceuticals in aqueous media by AOPs is likely to be an expensive venture. The
available literature on photolysis degradation of pharmaceuticals demonstrates that
photochemical AOP (UV/H 2O2) is a promising technology to reduce the effects of these
compounds (Pereira et al. 2007).
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CHAPTER 3
MATERIALS, METHOD, AND ANALYTICAL
DETECTION

3.1

Introduction

The accurate detection of target analyte of emerging contaminants is an important in step
the development of strategies for the treatment of these compounds. Thus, the
identification or development of a suitable and appropriate method, and preparation
techniques are important issues to be considered. This chapter discusses method for the
detection of ibuprofen and naproxen in selected water matrices. Consequently, the
preparation procedure, material used, sample collection, sampling site description, and
method validation are presented in detail.

Following the detection of lipid lowering clofibric acid, antidepressant imipramine, and a
number of other classes of pharmaceuticals, post-therapeutic fate and effects of
pharmaceuticals have emerged as an issue of widespread environmental interest over the
decades.

It is now

unequivocally proven that pharmaceuticals

are emerging

environmental contaminants and people from different fields are closely monitoring their
ubiquitous persistence. Global awareness that such pharmaceuticals (also known as
organic micropollutants) can contaminate the environment, even at trace levels, has
driven the development o f more sophisticated and sensitive analytical tools for their
detection in aqua environmental samples. Most techniques involve a pre-concentration,
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clean-up of the extracts and chromatographic separation by gas or liquid chromatography
followed by high sensitivity detection.

Table 9 shows the chemical structure of a few PhACs (NSAIDs) including the targeted
compounds. The diversity of these pharmaceuticals, the complexity of environmental
matrices and the trace detection limits make the analysis of such compounds a
challenging issue for many researchers. Several analytical methods for measuring PhACs
in aquatic compartments have been published. Amongst these, the predominant analytical
techniques such as gas chromatography/mass spectrometry (GC/MS) (Koutsouba et al.
2003, Lee et al. 2003, Soliman et al. 2004, Thomas and Foster 2004, Weigel et al. 2004)
and

high-performance

liquid

chromatography/mass

spectrometry

(HPLC/MS)

(Vanderford et al. 2003, Loftier et al. 2005) are noteworthy. As the present study was
constrained to NSAIDs, particularly, ibuprofen and naproxen, different published
methods for their analysis were reviewed from previous studies (Moeder et al. 2000,
O' llers et al. 2001, Boyd et al. 2003, Koutsouba et al. 2003, Lee et al. 2003, Rodriguez et
al. 2003, Thomas and Foster 2004, Weigel et al. 2004, Tauxe-Wuersch et al. 2005). For
the purpose of the study, it was necessary to develop an analytical method that is
accurate, precise and practical. The method needed to be relatively fast and inexpensive,
requiring accessible instrumentation and the minimal use of hazardous reagents. The
analytical technique presented here allowed the reliable detection and quantification of
target pharmaceuticals in the selected water matrices.
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Table 9 : Chemical structure and properties of some commonly detected pharmaceuticals (NSAIDs)* in waters: (Rahman
2008, Ying et al. 2009)
Pharmaceutical

Therapeutic
use

CAS

MF

MW

Water
solubility
(mg/L)

Diclofenac

Analgesics

15307-86-5

C 14H 11CI2NO2

294.0

2.4

Ibuprofen

Analgesics

15687-27-1

Ci3Hi80 2

206.3

21

Naproxen

Analgesics

22204-53-1

C14H14O3

230.2

27

pA:a

log Kow

Structure

MF: Molecular Formula; MW: Molecular Weight; CAS: Chemical Abstracts Service Registry Numbers; pATa : -logio of Ka (acid dissociation
constant); log Kow : logarithm of octanol/water partition coefficient.

3.2

Materials and Methods
3.2.1 Compounds and Standards

Ibuprofen (> 98% GC) (a-Methyl-4-(isobutyl)phenylacetic acid) was purchased from
Sigma-Aldrich, Oakville, ON, Canada. Other common names for this compound are 2-(4isobutylphenyl)propionic

acid

or

a-Methyl-4-(2-methylpropyl)benzeneacetic

acid.

Naproxen (>98% GC grade) ((S)-(+)-6-Methoxy-a-methyl-2-napthaleneacetic acid) was
purchased from Sigma-Aldrich, Oakville, ON, Canada. Methylene chloride or
dichloromethane (DCM) was obtained from Caledon Laboratories Ltd, Georgetown, ON,
Canada. Its formula is CH2CI2. Dichloromethane is suitable for trace organic and
pesticide analysis for the application of GC/MS or LC/MS. BSTFA (Trimethylsilyl 2,2,2trifluoro-N-(trimethylsilyl)acetamidate) with its highest purity (99.6%) was purchased
from Sigma-Aldrich, Oakville, ON, Canada. The CAS number is 25561-30-2. A very
common name of this chemical is N,0-Bis(trimethylsilyl)trifluoroacetamide. There were
144 ampoules in a purchased box, where each ampoule contained 0.1 mL BSTFA.
Anhydrous sodium sulfate (Na2S0 4 , ACS, > 99.0%) in powder form was obtained from
Sigma Aldrich (Oakville, ON, CA). Isopropyl alcohol 99% (CABDH1133-4LP) was
obtained from VWR International Mississauga, Ontario, Canada.

Concentrated

hydrochloric acid, HC1 (36.5-38.0%, ACS specification) was available in the laboratory
during the period of testing. Five hundred millilitres (500 mL) of hydrogen peroxide,
H20 2 (30%, ACS) was purchased from Chemstore, University of Western Ontario,
London, Ontario. For laboratory use, 30 wt% solutions of H2O2 are most common. All
chemicals and solvents were of high purity grades and were used without further
purification. Laboratory grade water was obtained with a Bamstead Easypure UV

43

Ultrapure water purification system (Bamstead, IOWA, U.S.A.) that produces Type II
water by passing tap water through a combined RO and UV system.

Materials: Supplies of 0.45pm cellulose nitrate membranes, gridded, sterile filter paper
(Whatman 7141-104) were obtained from VWR International (28297-732), Mississauga,
Ontario, Canada. Filter paper #4 9cm, 12.5 cm and 18.5cm were obtained from VWR
International (28460-063 28460-110, 28460-142), Mississauga, Ontario, Canada. These
filters are good for organic extracts during analysis. Vacuum filter equipment (60002266) assembled with a graduated funnel, aluminum clamp, support base and Erlenmeyer
filtering flask was obtained from VWR International, Mississauga, Ontario, Canada.
Separatory Funnel with PTFE Stopcock 500 mL (60003-930) and 250 mL (60003-972)
were obtained from VWR International, Secaucus, NJ, USA. Amber bottles 125 mL
(15900-136), 250 mL (15900-046), 500 mL (89093-908 or 15900-140), 1000 mL (15900142) with solid tops were using for this work and were obtained from VWR International,
Mississauga, Ontario, Canada. These amber bottles are processed (PC) and qualityassured (QA) contaminant free sample containers. Culture tubes 16x125 mm (89000-504)
were obtained from VWR International, Mississauga, Ontario, Canada. Glass amber vials
12x32 mm, 2 mL (5182-0556) with red rubber septa were obtained from Agilent
Technologies, New Castle DE, USA. For sampling IR313-0500 bottles along with
polyfoam-lined caps were obtained from VWR International, Secaucus, NJ, USA. These
bottles are USEPA specified and suitable to maintain water quality parameters. Amber
bottles 1000 mL and 500 mL with Teflon-lined caps were also used for sampling and
storage purposes. Other materials such as funnel short stem, volumetric flask, cork rings,
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beaker pyrex, graduated cylinder, and Erlenmeyer flask were obtained from Chemstore,
University of Western Ontario, London, Ontario.

Instrument: BUCHI Rotavapor® R-210/215 with BUCHI Heating Bath B-491 (BUCHI
Labortechnik AG, Flawil, Switzerland) is an advanced model of Rotary Evaporator
(Figure 4). With vacuum controller, vacuum pump, recirculating chiller, rotation drive
control (20-280 rpm) and controlled temperature (20-180°C) this equipment allows
evaporation of solvents in the most efficient and gentle way. The water bath used was
capable of maintaining temperature within ±2°C.

Figure 4 : BUCHI Rotavapor R-210/215 with BUCHI Heating Bath B-491
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The Hach Model 2100AN IS Laboratory Turbidimeter (Cleartech Industries Inc,
Mississauga, ON) was used for turbidity measurement. The 2100AN IS Laboratory
Turbidimeter provides direct measurements in units of NTU (Nephelometric Turbidity
Unit) in a range 0-10,000. DR 5000 UV-Vis Spectrophotometer (Cleartech Industries Inc,
Mississuaga, ON) and was used for the measurement of color, % Transmittance,
Absorbance and water spectra reading.

The GC/MS system utilized was an Agilent 7890A gas chromatograph directly interfaced
with an Agilent 5975C mass selective detector (Agilent Technologies, New Castle, DE,
U.S.A.) equipped with a G1701EA MSD productivity Chemstation software and
supported by a G1033A NIST 05 MS library system (Figure 5). DB-5 capillary column
(Agilent Technologies, New Castle, DE, U.S.A.) was used for compounds separation.
The boiling points of ibuprofen and naproxen are 212 °C and 212-251°C
(Lerdkanchanapom and Dollimore 1997) respectively. On the other hand, the aqueous
solubility of these compounds is 27 mg/L for naproxen and 21 mg/L for ibuprofen (see
Table 9). For such less polar and high boiling point compounds, a DB-5 column is the
most suitable column for analytical purpose as indicated by most literature. Moreover,
according to Agilent application department the most recommended column for this
purpose is the DB-5 column. Hence, the present work was carried out using a DB-5
capillary column (30 m x 0.25 mm id., film thickness 0.25 jum) which is non-polar and
the highest temperature limit was 350°C with (5%-Phenyl)-methylpolysiloxane stationary
phase composition. This non-polar, low bleed, capillary column is used widely for
analyzing high temperature samples at trace concentrations. Because this type of column
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has excellent inertness for active compounds including acidic and basic compounds, the
study selected it for the separation of targeted acidic pharmaceutical compounds.

Figure 5 : Gas chrom atography interfaced with mass spectrometry

3.2.2 Sample Preparation
3.2.2.1 Stock Solution Preparation
Stock solutions of the analytes were prepared by weighing out 20 mg of the powdered
standard and were dissolved the contents in a dilution solvent. Most stock solutions used
in published studies have been prepared with dichloromethane, methanol, acetone,
trichloroethylene; however, based on solubility, dichloromethane (DCM) was used in the
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present study. A few published papers have suggested stock solutions in water. In general
most literature use dichloromethane to prepare stock solutions as most analytes are more
soluble in DCM than in other solvents (Boyd et al. 2003). The concentration of the stock
solutions was 100 mg/L. Exactly 20 mg analyte was dissolved in 151.5 mL DCM to
achieve the target stock concentration by adjusting the volume of DCM, as DCM is a
DNAPL (Dense non-aqueous phase liquid). Thus stock solution of each individual
compound at 100 mg/L concentration was prepared by dissolving the standard in
dichloromethane (DCM) or methylene chloride. As the volume of DCM was already
adjusted during stock preparation, hence, during dilution carried simultaneously in water,
no further adjustment of concentration was needed. The stock solutions were used to
prepare spiking solutions, calibration standards and sample solutions. Stock solutions
were prepared every two months. It is important to correct stock solutions concentrations
at this preparation step so that subsequent standard solutions can be prepared with
accuracy. All stock solutions were stored in the refrigerator to protect them against
photodegradation. They were warmed up to room temperature prior to use.

3.2.2.2 Standard Solution Preparation
The calibration standards consisted of known concentrations of the analytes in a water
solution. Standard solutions were prepared in water from stock solutions using
appropriate aliquots. As our target was to analyse water samples, it was important to
prepare the standards and other solutions in water and ensure consistency throughout the
work. Standard solutions were prepared by combining aliquots of individual stock
solutions and diluting the mixture with water. At least twelve standards at a range o f
0.01 pg/L to 1OOOpg/L were prepared using 50 mL laboratory grade water (LGW). All
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standard solutions were stored at 4°C in screw-cap amber glass bottles with Teflon liners
in the dark. Further working standard solutions were made from calibration standard
solutions by diluting with water at appropriate concentrations on the working day.

Extraction: The majority of techniques currently applied for enrichment of organic
analytes from liquid samples are based on extraction and utilized solid absorbents or
organic solvents. The most promising and most frequently used techniques of sample
preparation are liquid phase extraction, liquid phase microextraction, analyte isolation by
the use of sorbents or adsorbents and sometimes a single chosen technique such as solid
phase microextraction (SPME) (Rawa-Adkonis et al. 2003, Smith 2003). Though, each
and every techniques show many favourable characteristics; nevertheless, they also have
their own limitations. According to Moeder et al. (2000), though SPE offers greater
variability in analyte enrichment, this important advantage of SPE is accompanied by
simultaneous accumulation of matrix substances and often necessitates the use of
additional clean-up steps. The much faster and simple SPME can be used in conjunction
with GC/MS. However, higher contents of organic matter can block the fibre surface and
impede SPME analysis.

Liquid-liquid extraction (LLE) is one of the oldest ways of solvent extraction techniques
for sample preparation and purification. However, it is still popular for its simple
technique of phase switching as well as intensive isolation of organic analytes from any
water matrices (Rawa-Adkonis et al. 2003, Smith 2003). In LLE, organic compounds
originally present in the sample pass to an organic phase o f extractant that is suitable for
employing a capillary gas chromatography. In the simplest form, extractant and sample
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are shaken in one container. Here, the analytes are transferred directly from the primary
sample to the water immiscible organic phase. Rawa-Adkonis et al. (2003) and Smith
(2003) have observed that in order, to achieve high extraction recoveries, usually large
amounts of the organic extractant must be applied.

LLE with DCM followed by gas chromatography/mass spectrometry (GC/MS) analysis is
described under the U. S. Environmental Protection Agency (EPA) Method 625 for the
determination of extractable organic pollutants in water (USEPA 1984). In the present
study, LLE was carried out using 50ml solutions in separatory funnels. Each 50 mL of
solutions was then extracted two times with 25 mL aliquots of methylene chloride
(DCM) at 1:1 ratio. First, 25 mL o f methylene chloride was added to the solution bottle
and, shaken for 30 seconds to rinse the inner surface. After that, the solvent was
transferred to the separatory funnel and extracted by shaking the funnel for two minutes
with periodic venting to release excess pressure. Then, the mixture was allowed to
separate into organic phase and water phase. As DCM is a DNAPL, the organic layer
collected at the bottom of the water phase. Again, the second 25 mL volume of methylene
chloride was added to the solution bottle and the extraction procedure was repeated. The
extracts were combined for a total of approximately 50 mL methylene chloride in the
amber bottles. Anhydrous sodium sulphate was added to the extract and then removed by
gravity filtration.

PreConcentration with RotaVapor: As the extracts need to be further concentrated to
allow the detection of trace molecules, the dried extract was rotary evaporated by using
BUCHI Rotavapor® and a water bath that was maintained at 38°C (±2°C). A rotation
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speed of 280 rpm, 100 mL flask and adjusted vacuum with atmosphere pressure of 850
mbar was used, as recommended for DCM at 40°C (www.buchi.com/rotaryevaporator rotavapor). After complete evaporation, the extract was then reconstituted
with 1 mL DCM and manually shaken to dissolve the residue. The residue was then
transferred to a 2 mL amber autosample vial and capped with blue screw lid.
Derivatization: Due to the lack of volatility and thermal stability most of the
pharmaceuticals need to be derivatized in order to be compatible with GC analysis. The
main purpose of analytical derivatization is the enhancement o f the volatility of analytes
by decreasing the polarity of carboxylic (COOH-) or phenolic (OH-) functional groups or
increasing the thermal stability. The choice for selecting derivatization of acidic
pharmaceuticals containing carboxylic moieties are given by silylation with N ,0bis(trimethylsilyl)

trifluoroacetamide

(BSTFA),

acylation

with

trifluoroacetic

anhydride(TFAA), and benzylation with pentafluorobenzyl bromide (PFBB), or
methylation with trimethylsulphonium hydroxide (TMSH) or diazomethane (CH2N 2)
(Moeder et al. 2000, Oilers et al. 2001, Temes 2001, Rodriguez et al. 2003). In the
present study BSTFA was used as a derivatizing agent. The pharmaceuticals analysed in
the study contain carboxyl functional groups and for such compounds BSTFA has found
widely used silylating agent (Boyd et al. 2003, Lee et al. 2003, Thomas and Foster 2004).
Two hundred microlitres (2 x 0.1 mL ampoules) of BSTFA was added to the
reconstituted extract in the vial and maintained at 60°C for 20 min to allow completion of
the reaction.
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3.2.2.3 Real Water Sample Preparation
Real water samples were obtained from wastewater treatment plants and drinking water
treatment plant. In order to remove suspended material, the aqueous samples were
vacuum filtered through 0.45 pm cellulose membrane filter. Because water samples, in
particular wastewater samples, usually contain a high loading of organic material and
suspended particles, filtration was the first step of sample preparation. Moreover, sample
clean up or selective extraction may be used to control interferences from organic matter
as cited by Castiglioni et al. (2005). Therefore, this work focused on the sample
preparation steps prior to laboratory analysis and in water treatment. The samples were
acidified to pH 2 as water samples are normally stabilised at that pH to obtain the
undissociated form of the analytes. Hence, in this work concentrated aqueous
hydrochloric acid (HC1) was used for this purpose. Samples were extracted using LLE as
described earlier. Subsequent extract collection, concentration and, derivatization were
performed as described before. In brief, the sample clean up and extraction scheme is
described in Figure 6.

3.2.3 M ethodology
Besides improved preparation and clean-up reliable analytical technique based on an
enrichment step, chromatographic separation and mass spectrometric determination with
and without derivatization is fundamental for any water matrix analysis.
3.2.3.1 GC/MS Analysis Method

GC/MS is a widely used analytical technique for residue analysis of pharmaceuticals. The
major advantage o f this technique is the fact that the electron impact (El) ionization mode
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is less affected by the matrix interference of the sample than the liquid chromatography
(LC) techniques as indicated by different studies (Koutsouba et al. 2003; Metcalfe et al.
2003b). Because of the high separation power of capillary columns followed by a specific
detection by means of mass spectrometry the combined GC/MS technique is the most
appropriate tool for volatile and thermally stable compounds. GC/MS has an improved
selectivity and sensitivity compared to LC/MS for the detection of polar pharmaceuticals
and their metabolites in complex matrices (Temes 2001). Therefore, liquid-liquid
extraction (LLE) followed by concentration, derivatization and GC/MS analysis was used
for the detection of these polar acidic compounds in the present study.

Analytical Method Description: All standards and samples were analyzed for the selected
pharmaceuticals by gas chromatography/mass spectrometry (GC/MS) based on methods
previously described by Thomas and Foster (2004). Briefly, these acidic pharmaceutical
compounds were analyzed using an Agilent 7890A gas chromatograph directly interfaced
with an Agilent 5975C mass selective detector (Agilent Technologies, New Castle, DE,
U.S.A.). The GC/MS system utilized was equipped with G1701EA MSD productivity
Chemstation software and supported by G1033A NIST 05 MS library system. A DB-5
capillary column (30 m x 0.25 mm id., film thickness 0.25 pm.) was used for compounds
separation. Helium gas was used as the carrier gas and set at a linear flow rate of 1
mL/min. A splitless injection port liner was used for sample analysed in splitless injection
mode. The oven temperature was programmed as follows: 60 °C for 1.5 min, then 20
°C/min to 120 °C (0-min hold), then 4 °C/min to 160 °C (0-min hold), and then 12
°C/min to 250 °C for 12 min. The injector and interface temperature were set at 250 °C,
with the MS quad set at 150 °C and the MS source at 230 °C. The total analysis time was
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approximately 34 min. The mass spectrometer (MS) was operated in the positive electron
ionization (El) mode and following conditions were employed: 70eV electron energy,
selected ion monitoring (SIM) mode and 0.1 sec/decade high speed magnetic field
switching, 50-500 a. m. u. (atomic mass unit) mass range and 230°C ion source
temperature.

GC/MS Instrumentation Parameters : Separation and detection of the analyte was carried
out with the GC/MS system integrated with GC 7890A and MSD 5975C (Agilent
Technology).

Capillary column

: A fused-silica (DB-5; 30 m; 0.25 mm ID; 0.25 pm FD)

Injector

: splitless,

Injector temperature

: 250 °C

Injection volume

: 2.00 pL

Carrier gas

: Helium

Flow rate

: 1 mL/min

Temperature program : Oven = 60 °C (1.5 min), first ramp: 20 °C/min to 120 °C, second
ramp 4°C/min to 160 °C, third ramp 12 °C/min to 250°C and then held 12 min at 250 °C.
Analysis time

: 34 min

Interface temperature : 250 °C
Scan mode

: Selected Ion Monitoring (m/z =50-500 a.m.u)

Ionization mode

: EI+/ 70 eV
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GC/MS Analysis Flowchart

Figure 6 : The procedures involved in the extraction and analysis of selected
pharmaceuticals in water matrices
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Blank Sample Analyse: Blank samples were prepared along with the actual samples each
time and with the same process as the samples prepared.

3.2.3.2 Calibration
Quantification was performed using external calibration. Calibration curves were created
from six to eight points in the concentration range 0.01 pg/L to 1000 pg/L. At least twelve
samples with known concentrations of each pharmaceutical analyte were prepared on an
aliquoting basis using the procedure described in the section on standard preparation.
Using external calibration process, the calibration curve for each pharmaceutical was
constructed by plotting a linear trend line of the pharmaceutical peak area against
concentration by taking the best fitted peak values. In order to estimate how closely the
estimated values for the trend line corresponded to the actual data, the regression
coefficient (R ) was calculated. GC/MS data were acquired by using the SIM technique.
The peak areas were plotted against the corresponding concentration of the analytes using
this SIM. The resulting calibration curves for the target analytes are shown in Figure 7(a)
and (b).

The calibration curves for the analytes were obtained for a wide range of concentrations
to cover typical environmental detection levels. The analytes were expected to be present
in higher concentrations in wastewaters than in surface waters. Linear regression
coefficients (R2)

were

>0.995 in both cases, indicating very good linearity of the

calibration curves as shown in the Figure 7 (a) and (b).
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Figure 7 : Calibration curve (SIM) from GC/MS analysis for the target analytes (a)
ibuprofen and (b) naproxen
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3.2.4 Study Sites
For the investigation of occurrence and removal of ibuprofen and naproxen from
wastewater and surface water, samples were obtained from selected treatment plants in
southwestern Ontario. The study was intended to determine the presence of the selected
pharmaceuticals in different water sources.

3.2.4.1 Site Description & Sample Intake points for WW
The City of London (southwestern Ontario, Canada) operates six Pollution Control Plants
namely: Greenway, Pottersburg, Vauxhall, Adelaide, Oxford and Lambeth (Southland).
The combined average daily flow through the treatment plants is approximately 216,000
cubic metres per day (47.5 million gallons per day) in 2008. All the sewage receives
primary and secondary treatment, by what is known as an activated sludge process,
phosphorous removal by chemical addition and then disinfected using ultra violet light
before being discharged into the Thames River. The general operation profile of these
activated sludge sewage treatment plants consist of screens, grit removal, primary
settling, activated sludge process, final clarification and disinfection. The sample intake
points are shown in the Figure 8.
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Activated Sludge Process
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Figure 8 : GPCP sample intake points. Influent samples were taken from after grit
removal and final effluent samples from post Ultra Violet disinfection process. One
sample was collected from final clarifier in M arch, 2010.
The detailed description of the STP can be found elsewhere (www.london.ca). Briefly, at
the first steel screens with 12.7 to 19 mm openings, large material such as paper, and
plastic, are removed and then disposed of in a landfill. This helps prevent clogging of
equipment. For grit removal purpose heavier inorganic solids are removed using a vortex
system. This is done to protect subsequent treatment equipment from excessive wear. The
vortex units are enclosed to prevent odours from escaping and are connected to a
chemical scrubber to neutralize any odours. The grit is generally free of organic material
and is suitable for disposal at a sanitary landfill site. The Primary Settling (Tanks) units
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are designed to remove the larger organic solids and grease. The solids settle out by
gravity and the grease forms a scum which is skimmed from the surface o f the tanks. The
effluent from the primary tanks flows to the aeration tanks where it is treated biologically
to stabilize the dissolved and finely suspended impurities. The treatment process
employed is called the activated sludge process and involves the use of bacteria and other
minute organisms which, in the presence of air, utilize and consume the undesirable
constituents of the wastes in their life cycle. The air is supplied primarily through dome
shaped diffusers located at the bottom of the tanks to supply oxygen to ensure a large
mass of bacteria thrive. The effluent from the aeration tanks, called the "mixed liquor",
passes to final tanks where the suspended solids settle out by gravity as activated sludge
and is removed. The clear supernatant liquid being decanted over the weirs is discharged
to the disinfection process. Part of the activated sludge is returned to the aeration tanks to
maintain the mass of bacteria (activated sludge process) and the remaining excess sludge,
or "waste activated sludge", is pumped to one of three flotation units, where the sludge is
mixed with polymer and air to aid in the thickening process. The thickened sludge is
stored in holding tanks. The excess activated sludge from the other five operating plants
is hauled to the Greenway Pollution Control Centre. Before the treated effluent is
discharged to the river, between April 1 and September 30, it is disinfected to destroy
pathogenic bacteria. The treated sewage passes by Ultra Violet lights in a channel.
Disinfection by ultra-violet light is monitored by intensity monitors.

Among the six STPs, wastewater samples were collected from two largest treatment
plants: Greenway Pollution Control Plant (GPCP) (Figure 9) and Adelaide Pollution
Control Plant (APCP), which receives wastewater from domestic usage as well as
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discharges from major hospitals and local industries. In Greenway Pollution Control
Plant (GPCP), the annual average flow was 122 ML/day (million litres per day) and the
average daily plant peak flow was 238,000 cubic metres per day in 2009. The annual
average flow for the Adelaide Pollution Control Plant (APCP) was 27,399 cubic metres
per day and the daily average peak flow in 2009 was 68,077 cubic metres per day. The
sites were selected within a reasonable distance of the laboratory facility to allow the
samples to be extracted the same day as collected. The duplicate raw (influent) samples
were collected from the section after screen and grit removal. The effluent samples were
collected at the point o f post disinfection process. Sampling was carried out at two
months interval during March to September 2010. The only exception was the September
sampling where two samples were taken in one month to facilitate the treatment work.
Total ten times batch samples were collected throughout the study period. All samples
obtained were grab samples.
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Figure 9 : Greenway Pollution Control Plant (GPCP)

3.2.4.2 Site description & Sample Intake points for SW
Approximately 5,000 square kilometres of the city of London, Ontario is supplied by two
water treatment systems, namely the Lake Huron Primary Water Supply System and the
Elgin Area Primary Water Supply System. The source of SW in the study was Lake Erie
and the water samples were collected from Elgin Area Water Treatment Plant (EAWTP)
that uses Lake Erie as the source of drinking water. The lake sites are quite remote from
any direct wastewater sources. The Elgin Area Water Treatment Plant (WTP) employs
pre-chlorination, screening, powder activated carbon addition (seasonally on an asrequired basis), coagulation, flocculation, sedimentation, dual-media filtration, UV
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disinfection (as required), post-chlorination, and fluoridation to treat raw water obtained
from Lake Erie. The plant has a current treatment capacity of 91 million litres per day (20
million Imperial gallons per day) and serves a population of approximately 112,000
people. The drinking water system is monitored at various locations throughout the
system via a Supervisory Control and Data Acquisition (SCADA) system. Sampling for
surface water (SW) occurred during the fall (November sampling) when precipitation in
the region typically results in high water flows compared with dry summer months.
Replicate raw (untreated) water samples were collected in pre-cleaned one-litre amber
glass bottles from taps that were running (most facilities have the taps running
continuously).

3.2.4.3 Sample Collection and Preservation
The sample bottles were prewashed with LGW followed by isopropyl alcohol in the
laboratory. The bottles were then oven dried at 96°C for twenty four hours. At the
sampling spot, the sampling bottles were rinsed with the samples prior to fill up to the
top. Replicate influent (untreated) and effluent (treated) wastewater samples were
collected from GPCP and APCP from March, 2010 to September, 2010. The raw
(influent) samples were collected from GPCP and APCP after screen and grit removal.
All the effluent samples were obtained from post ultraviolet (UV) disinfection channels,
except the March sample due to the closure of the UV channel during that sampling
period. The samples were grab samples. Replicate samples were collected in pre-cleaned
one-litre amber glass bottles and the bottles were capped with clean Teflon-lined lids.
The samples were packed in cooler box (available in the lab) and returned to the lab as
soon as possible for immediate extraction and to avoid possible photodegradation. All the
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sample bottles were then stored in the dark at 4°C. For extraction of these acidic
pharmaceuticals, the samples were acidified to a pH of 2 by adding HC1.

Grab samples of raw surface water were collected on the 11th of November, 2010 from
EAWTP. Samples were placed in individual one-litre amber glass solvent-washed bottles
with Teflon-lined caps. Each of the sampling bottles was rinsed with the respective
sample prior to fill up. Samples were transported in an ice-cooled box to the laboratory
and stored at 4°C in a dark sample storage room. All samples were extracted within two
days of collection and treatment work carried on subsequently.

In a stability study,

Servos et ah (2007) spiked tap water with selected compounds at a concentration of 0.2
pg/L, analysed them over a period of 0-15 days and found these pharmaceuticals were
stable under acidified condition and proper preservation in the dark at 4°C. It should be
mentioned that a number of pharmaceuticals are stable over a period of time, except
salicylic acid, which has been found to be unstable susceptible to decrease in
concentration to trace levels within the first twenty four hours of storage (Servos et ah
2007).

3.2.5 Real W ater Sample Analysis
The real water samples obtained from different treatment plants underwent water quality
parameter testing (WQPT) and selected pharmaceuticals testing.

3.2.5.1 Water Sample Analysis for WQPT
The tested water quality parameters (WQPs) were pH, temperature, turbidity, alkalinity,
total organic carbon (TOC), color, UV absorbance and transmittance. The water quality
parameter data (WQPD) were obtained in the lab using available analytical instruments
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as well as supplied by water treatment facilities in some instances. The pH was measured
with a HQ 30d flexi HACH pH meter and the buffered solutions used for the calibration
were pH 4, pH 7 and pH

10 (obtained from VWR). A DR 5000 HACH

spectrophotometer was used for color, absorbance and transmittance test. HACH 2100 IS
Turbidimeter was used for turbidity test. For the alkalinity test, 785Metrohom auto
titrator was used. Temperature at the study site was also recorded. TOC data was
provided by wastewater plants for only two sampling dates. The results of WQPD are
given in section 3.3.3.

3.2.5.2 Water Sample Analysis for Target Compounds
The GC/MS method was applied for the analysis of real water samples obtained from
wastewater and surface water from the water treatment plants

for targeted

pharmaceuticals. Samples preparation and analysis have been previously described.
Concentrations of the selected drugs found in the matrices are listed in section 3.3.2.

3.3

Results
3.3.1

Data Analysis and M ethod Validation

SIM Identification: Selected ion monitoring (SIM) is a technique in which a particular
ion or a set of ions are selected and monitored. SIM experiments are useful for detecting
small quantities of a target compound or to eliminate overlapping by signals of a complex
mixture. This technique is also useful for trace analysis for a rapid screening of a large
number of samples for known target compounds. Therefore, in the study quantification
was performed by SIM using the most abundant and specific ions of each compound. The
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retention time which is also important in identification and the single ion masses of the
selected pharmaceuticals are listed in Table 10.

Table 10 : Table for retention time, molecular ion and characteristics ions for the
analytes
Analyte

Retention time (Rt)

Molecular Mass

Characteristics ions

(minute)
IBP

17.6

263

73, 117,160

NPX

22.6

302

185,243,287

The MS was operated in the selective ion mode as mentioned earlier. A quantitative and
qualitative ion was monitored for ibuprofen and naproxen. The chemical structure and
typical mass spectra of the silylated derivatives of the pharmaceutical analytes are shown
in Figure 10. The mass spectrum of silylated IBP indicates a molecular ion at mass-tocharge ratio (m/z) 263 and the major fragment ions appear at m/z 73, 117 and, 160. The
mass spectrum of silylated NPX indicates a molecular ion at m/z 302 and the major
fragment ions appear at m/z 185, 243 and, 287. These figures of mass spectrum for these
compounds were obtained from NIST mass library using the MSD Chemstation software.
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(a)

(b)
Figure 10: Electron ionization (El) mass spectra of the trimethylsilyl (TMS)
derivative of (a) IBP and (b) NPX
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As mentioned, BSTFA is a silylating reagent that converts compounds having COOHfunctional groups to the corresponding TMS derivatives. Therefore, after derivatization
with BSTFA, the analytes produced trimethylsilyl (TMS) derivative products. The
product formed as trimethylsilyl derivative of ibuprofen (IBP-TMS) was Benzeneacetic
acid, alpha.-methyl-4-(2-methylpropyl)-,trimethylsilyl ester. For trimethylsilyl derivative
of naproxen (NPX-TMS) the formed product was 2-Naphthaleneacetic acid,6-methoxyalpha.methyl-,trimethylsilyl ester, (+)-.

GC/MS chromatogram of the silylated products IBP-TMS and NPX-TMS that produced
using fused-silica capillary column (DB-5), splitless injector and gradient temperature
program as specified earlier are shown in Figures 11 and 12. Figure 11 shows the GC/MS
chromatogram for the analytes spiked at one pg/L prepared in laboratory grade water
(LGW). Figure 12 presents the chromatogram of the analytes obtained from the analysis
of wastewater sample (raw wastewater) under the same instrumental conditions. These
figures show that the signal response of an analyte detected in the field sample is similar
to the signal response detected in the spiked solution of standard.
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Method Detection Limit: The sensitivity of the method was evaluated by the limit of
detection (LOD) for each compound and this was estimated at 3 times the signal-to-noise
ratio (S/N). The method detection limit (MDL) is similar to a LOD, but is based on
samples, which passed all single method steps. A limit of quantification (LOQ) is
normally 6 to 10 times the MDL value and is considered to be the lowest concentration
that can be accurately measured and reported. Detection limits were determined by
analysis of multiple low-level samples in addition to blanks. A number of papers have
described the determination of limit of detection and limit of quantification based on S/N
ratio, for example, Yargeau et al. (2007). In the study, LOD was determined by taking
spiked (0.001 pg/L to 0.01 pg/L per analyte) Type II water samples (laboratory grade
water) through the entire procedure and calculating based on the S/N ratio. A blank
method using the same Type II Milli-Q water was processed along with the samples.
Method detection limits (MDL) were determined by taking several spiked samples at
concentrations of 0.01 pg/L to 0.05 gg/L through the entire procedure and estimating
based on S/N. The limits o f quantification (LOQ) were estimated as the amount of
analyte that produced S/N ratio of 10:1 in samples of wastewater and surface water
collected from the respective treatment plants that were spiked with a range of analyte
concentrations. The estimated method detection limit in different matrices is presented in
Table 11. Limit of detection (LOD) for both pharmaceuticals was determined to be 0.010
gg/L using laboratory grade water. Method detection limit (MDL) for ibuprofen in
sewage treatment influents and effluents were 0.045 gg/L and 0.035 gg/L respectively.
MDL for naproxen in sewage treatment influents and effluents were 0.040 gg/L and
0.030 gg/L respectively. In this study the observed detection limit and quantification
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were in a range that allowed the detection and quantification of these compounds in
wastewater and natural water. The minimum concentration of the analyte that the
instrument could detect with a S/N ratio of 3:1 was 0.010 pg/L for both compounds.

Table 11 : Limit of detection and limit of quantification obtained in SIM mode
Analyte

Linearity

LOD

LOQ

R2

(ng/L)

(ng/L)

WW Influent

WW Effluent

Surface Water

(AUVEf)*

(Raw)

MDL

MQL

MDL

MQL

MDL

MQL

(ng/L)

(ng/L)

(ng/L)

(ng/L)

(ng/L)

(ng/L)

Ibuprofen

0.998

10

60

45

360

35

300

25

150

Naproxen

0.999

10

60

40

300

30

250

25

150

*AUVEf: After UV treated effluent

Recovery: To validate the analytical method against any possible interference from
factors such as sample preparation, direct influence of extraction, signal response and
signal suppression, recovery is an important consideration. The percentage recovery of
the analytes usually is calculated by (3.1).

R = ±3LZ ^23LX

^std

wo..

...(3 .1)

Where,
Rc= Percentage recovery,
Asp=Area of spiked sample
A„sp=Area of non-spiked sample
Astj= Area of standard solution
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Table 12 :

Percent recoveries of ibuprofen and naproxen (mean±standard

deviation) from spiked laboratory grade water and wastewater effluent samples
(n=4)*
Analyte

LGW

WW Effluent

0.1 pg/L

1 pg/L

200 pg/L

0.1 pg/L

1 pg/L

200 pg/L

IBP

89±12

92±11

96±16

85±15

89±18

87±14

NPX

94±9

103±13

99±6

87±12

91±15

93±9

* N u m b e r o f re p lic a te m e a s u re m e n ts

Recovery tests were conducted for a range of concentrations using 50 mL water spiked
with 0.1 pg/L, 1 pg/L, 200 pg/L for each analyte. In the case of wastewater,
contaminated free samples were used for the recovery test. For that purpose, samples
were obtained from GPCP and analysed prior to the recovery test. Similarly, surface
water from Lake Erie was used for the recovery test to evaluate the matrix effect. Blank
samples were run along with the test samples. The recoveries of the spiked analytes at
different concentrations (0.1 pg/L-200 pg/L) by means of GC/MS ranged between 80%110% in different matrices. For wastewater the recoveries of the spiked analytes from
different concentrations (0.1 pg/L-200 pg/L) were 85-93% based on GC/MS, whereas for
LGW the recoveries of the spiked analytes from similar concentrations were 89-103%
(Table 12). Overall, recoveries after filtration, extraction, derivatization and clean-up
generally exceeded 70% in the study.
The obtained recovery values of the pharmaceuticals compared favourably with rates
reported in previous studies (Thomas and Foster 2004, Yargeau et al. 2007). In the
present study, each sample was analysed in four replicates and the reproducibility was
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calculated by the standard deviation of the measurements. The standard deviation of the
replicate samples was usually less than twenty percent, which provided reasonable
confidence in the data.

3.3.2 Analysis o f Real W ater Samples by GC/MS
The results of the analysis of samples collected from the wastewater treatment plants and
surface water treatment plant for the selected pharmaceuticals are summarized in Table
13. Quantification was made by comparison with prepared standards. The occurrence of
the targeted acidic drugs (ibuprofen and naproxen) was observed in two sewage treatment
plants (STPs) over a certain period. The results of the sample analysis show that these
substances are persistent in wastewater influent which is not unexpected. The result
showed ibuprofen was more frequently detected, whereas, naproxen was detected once in
raw wastewater. The results further suggest that these highly consumed pharmaceuticals
could persist in wastewater effluent even at trace concentrations.
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Table 13 : Concentrations (|ig/L) of the investigated compounds in Sewage and SW
Sampling
date

WTP

Condition

Target
Analyte

WW Matrix
(Influent)

WW Matrix
(AUVEffluent)

25/03/2010

GPCP

unspiked

IBP

17

n.a

NPX

n.d

n.a

IBP

3

< 0.035*a

NPX

<0.040*a

n.d

IBP

<0.045*a

n.d

NPX

n.d

n.d

IBP

7

NPX

12

< 0.030*a

IBP

n.d

n.d

NPX

n.d

n.d

IBP

n.d

n.d

NPX

n.d

n.d

28/05/2010

28/07/2010

29/07/2010

16/09/2010

29/09/2010

1 1

/1 1 / 2 0

10

GPCP

GPCP

APCP

GPCP

GPCP

EAWTP

unspiked

unspiked

unspiked

unspiked

unspiked

unspiked

SW
Matrix
(Raw)

*

♦o

< 0.035

n.d

IBP

NPX
n.d
----- *----------- ---na : not analysed (Analysis was not done as post UV (AUV) treated sample was not available during
sampling; n.d: not detected; *a: <MDL

However, the usage patterns, removal efficiency of these prescribed and nonprescribed
drugs may also vary throughout the year, contributing to variability in the concentrations
of PhACs within the watershed. As the study was not designed for monitoring the PhACs
over a regular period, hence, further analysis should be done to study these variations and
identify the main factors influencing the behaviour of PhACs in the wastewater
watershed. The possible reason for absence of these PhACs in surface water samples
could be the influence of high flow rate during the sampling period. Other studies have
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also reported the decline in concentration observed in the fall (Kolpin et al. 2004,
Yargeau et al. 2007).

In general, the removal of these pharmaceuticals in wastewater treatment plant depends
on the residence time of wastewater in the STPs. In a study Tauxe-Wuersch et al. (2005)
showed that the removal of ibuprofen depends on the residence time of wastewater in the
STPs. A long retention period induces a decrease in the removal of ibuprofen. Moreover,
these STPs (in the study) have ultra violet disinfection process which could facilitate the
removal efficiency for many pharmaceuticals, except few recalcitrant compounds such as
ibuprofen that does not easily respond to photodegradation. The photodegradation
response of these pharmaceuticals is elaborated and demonstrated in chapter 4.

No possible matrix interference was observed during the real water samples analysis in
the study. The signal intensity of an analyte detected in the field sample was similar to the
signal intensity detected in a standard solution as shown in Figures 11 and 12,
respectively, in the section on SIM identification under 3.3.1. In general, the major
advantage of using GC/MS with positive electron impact (El) ionization mode is
overcoming possible matrix interference in comparison with LC/MS with ESI where
matrix effects can occur during the ionization of the analytes in the source interface
(Petrovic et al. 2005). During the application of any analytical method, the identification
and correction for possible matrix effects must be accomplished to achieve accurate
measurements.

In the present work, matrix effect from wastewater influent and effluent was minimized
by taking additional measures, such as improved clean-up, proper filtration, acidification,
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extraction procedures to reduce the amount of matrix entering the instrument, reducing
the flow rate of the sample matrix in the ionization source, and decreasing the injection
volume. The implementation of these measures was useful in reducing matrix effects,
however, it was time consuming and labour intensive.

The results of the present study show that the concentrations of pharmaceuticals detected
in the wastewater are consistent with those reported in wastewaters elsewhere in Ontario
(Lee et al. 2003). Overall, these results demonstrated that pharmaceuticals are distributed
in wastewaters within a watershed in southwestern Ontario at concentrations similar to
levels observed in previous studies undertaken in other parts of North America (Miao et
al. 2002, Boyd et al. 2003, Metcalfe et al. 2003a, Thomas and Foster 2004).

3.3.3 Analysis o f Real W ater Matrices for W ater quality
Param eter Test (W QPT)
The WQPT results obtained for the grab samples of wastewater and surface water are
shown in the Table 14 and Table 15 respectively. The pH of the influent was in the range
of 6.7 to 7.4 and 7.1 to 7.45 of the effluent sample. UVT254 and UVabs254 were
measured immediately after filtration and the values were close for all the effluent
samples except the March sample, which was collected from final clarifier. Turbidity
values were taken immediately following the arrival of the samples in the laboratory and
were found to be higher for the influent samples than for the effluent samples, as
expected. TOC data were provided by the STPs fort two sampling periods. Color test
values were recorded occasionally depending on the availability of the standard color
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solution and were reported as true color. For the color test filtered water samples were
used. For the influent and effluent samples alkalinity ranged from 254 to 320 mg/L as
CaCC>3 and 123 to 200 mg/L as CaCC>3 respectively.
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Table 14 : Table fo r W QPD fo r W W
Dated

WWTP

Temp (°C)

pH

Turbidity

Color

Alkalinity

(NTU)

(ptCO)

(mg/L as

TOC

UVT 2 54

Abs254

(%)

CaC03)

25/03/2010***

In fl

E ffl

I n fl

E ffl

In fl

E ffl

In fl

E ffl

In fl

E ffl

In fl

E ffl

I n fl

E f fl

In fl

E ffl

GPCP

2 1.1

25.3

6.99

7.16

57.7

1.49

455

32

254

123

n.a

n.a

45

65.3

0.346

0.185

GPCP

18.6

2 0 .1

7.14

7.45

55.3

4.13

320

28

289

166

n.a

n.a

68.9

95.8

0.162

0.019

GPCP

23.6

24.5

7.26

7.30

49.8

1.45

n.a

n.a

320

20 0

26

12 0

75.6

93.5

0 .12 1

0.029

APCP

2 0 .1

20.7

7.40

7.10

65.5

5.60

345

28

278

140

n.a

n.a

54.3

91.0

0.265

0.041

GPCP

22.7

23.3

7.21

7.37

52.7

1.34

n.a

n.a

260

161

68

7.75

n.a

95.0

n.a

0 .0 2 2

GPCP

21.3

2 0 .6

6.70

7.40

38.6

1.60

n.a

n.a

n.a

n.a

n.a

n.a

n.a

93.7

n.a

0.028

(Thursday)
28/05/2010
(Friday)
28/07/2010*1
(Wednesday)
29/07/2010
(Thursday)
16/09/2010*2
(Thursday)
29/09/2010
(Wednesday)
Infl=WW Influent
Effl= WW Effluent
*on March 25, 2010 WW Effluent was collected from secondary effluent as UV disinfection section was closed during that time. The other dated effluent was
all from AUV (after UV disinfection).
** Data provided from GPCP, See Appendix A.
*2

Data provided from GPCP, See Appendix A.

n.a= not analysed

Table 15 : Table fo r W QPD fo r SW
Dated

11/11/2010

WTP

EAW TP

(Thursday)

Water

Temp

Matrix

(°C)

Surface

8.89

Water
(Raw)

n.a=not analysed

pH

8.34

Turbidity

Color

Alkalinity

(N TU)

(pt CO)

(mg/L as CaCOs)

16

5

98.51

TOC

n.a

U V T 254

AÒS254

(%)

( c m 1)

93.9

0.027

3.4

Conclusion

Gas chromatography/mass spectrometry (GC/MS) is a widely used analytical technique
for residue analysis of pharmaceuticals. The major advantage of this technique is that the
electron impact (El) ionization mode is less susceptible to matrix interference of the
sample than liquid chromatography (LC) as indicated in different studies. The present
study demonstrated that the use of LLE and GC/MS are effective analytical techniques
for determining and screening the presence of selected pharmaceuticals in aquatic
environmental matrices. In order to achieve high extraction recoveries large amounts of
the organic extract (dichloromethane) was applied and the ratio was maintained 1:1
throughout the procedure and consistency maintained during standard preparation and
sample preparation process. In this work, LLE provided an improved selectivity in terms
of chromatogram peak separation, reproducibility and high recoveries of trace
pharmaceuticals. The analytical procedure involved many interrelated steps including
sample pre-treatment (filtration), pre-concentration (LLE), concentration (rotavapor) and
derivatization (BSTFA). In addition, quality control procedures were followed, including
appropriate replicate sampling, proper sample handling and preservation, and suitable
blanks run along with the samples and standards.

In a study, Yook et al. (1994) compared LLE and SPE coupled with GC/MS as
preconcentration procedures and confirmed that LLE yielded better efficiency over SPE
for semivolatile priority pollutants. For LGW samples the recoveries of the spiked
analytes at constant sample volume (50 mL) and concentration (0.10 pg/L-200 pg/L)
were 89-103 % by means of GC/MS. As both compounds show high solubility in DCM,
they are recovered by organic solvent, and thus the applied LLE procedure ensured
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effectiveness. The method detection limits were in the range 0.01 pg/L to 0.045 pg/L for
GC/MS for the target analytes.

The analytical method was applied for the analysis of wastewater samples from two
London treatment plants and surface water sample from Elgin area water treatment plant.
The observed concentration of the target compounds in the WW influent was n.d-17
pg/L. Although the concentrations of ibuprofen and naproxen were found to be low in
these STPs, it is likely that they may occur at relatively high concentrations based on
increased use and consumption in future, which may result a potential contamination of
surface water. Specially, during winter period when photodegradation occurrence is
unlikely and the UV disinfection system is not operating, these pharmaceuticals could get
into natural water and subsequently mixed with potable water. Thus, there is the
possibility

that

people

could

consume

these

compounds

unintentionally/unwittingly, which can have a subtle health effect.
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CHAPTER 4
REMOVAL OF IBUPROFEN AND NAPROXEN
FROM WATER MATRICES USING UV/H20 2
AOP

4.1

Introduction

Pharmaceutically active compounds (PhACs), which are used in large amounts
worldwide, have caused concerns because increasing amounts have been detected in
wastewater treatment plant effluents and in lakes, rivers and ground waters. As
conventional water treatment processes are ineffective for removing low concentrations
of PhACs (Temes 1998, Daughton and Temes 1999), advanced oxidation processes
(AOP) have gained considerable attention recently. Special attention should be given to
PhACs that have been found to resist water treatment and have, as a consequence, been
detected in drinking water, which includes some recalcitrant compounds such as
ibuprofen and naproxen belonging to non-steroidal anti-inflammatory drug group. The
study of Rahman (2008) showed only 41% removal for ibuprofen during O3/H 2O2 based
pre-coagulation AOP, where the initial concentration was low. Recently extensive
research has been conducted to remove pharmaceutical compounds and, other emerging
contaminants in the aquatic environment. UV based AOP has several advantages over
other processes for the treatment of water. An important advantage of UV disinfection is
that, it does not produce any known disinfection by-products (DBPs). Another advantage

82

of UV over other primary disinfectants, such as ozonation is the elimination of bromate
formation when bromide-containing waters are ozonated. UV is an effective disinfection
process that can degrade organic compounds by direct photolysis as a consequence of
light absorption, or indirect photolysis where photolysis of hydrogen peroxide, an
advanced oxidation process (AOP), leads to the formation of highly reactive,
nonselective, and short-lived hydroxyl radicals (-OH) as shown in reaction (RA):

H zOz + h d -> 2 ■O H ... ........ (R. 1 )

Where h is Planck’s constant (6.6261 x 10‘34 J-s), and ■&is the frequency in s'1.

A few degradation studies of PhACs by UV light and UV/H2O2 based AOP treatment
exist. Vogna et al. (2004) studied the degradation of the anti-epileptic drug
carbamazepine and consequent formation of intermediates by low pressure (LP) direct
(UV) and indirect (UV/H 2O 2) photolysis. They found that carbamazepine degradation,
negligible by LP direct photolysis, was enhanced by UV/H 2O2 AOP. Thus, PhACs that
belong to the anti-inflammatory drug group are investigated for UV based treatment and
reported in this chapter.

The degradation experiments were carried out under appropriate and standardized
conditions at Trojan Technologies laboratory, London, Ontario, where the radiometer, the
collimated beam set-up, and Petri dish placement were calibrated prior to the
experiments.
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4.2

UV Reactor and Experimental Set-up

This section outlines the reactor parameters, UV reactor set-up, and methods that were
used for the degradation work. Exposure time calculation based on fluence, absorbance
spectra of analytes corresponding to photodegradation and, water absorbance spectra of
the sample solution are discussed here, as they all are relevant to degradation
experiments.

4.2.1 Reactor Param eters
The treatment was carried out using two bench scale UV apparatuses, named quasi
collimated beam (CB). One o f the UV apparatuses was equipped with low pressure (LP)
lamp industrially termed as low pressure collimated beam (LPCB), and the other one was
equipped with medium pressure (MP) lamp commonly known as medium pressure
collimated beam (MPCB). The key difference between the two lamps is their emission
spectra; LP lamps emit nearly monochromatic light at 253.7 nm, whereas MP lamps emit
over a broad range of wavelengths between 200-600 nm (Stefan 2004). A 60 W low
pressure mercury vapour lamp was used for the LPCB while a 3 kW medium pressure
mercury vapour lamp was used for the MPCB. Figure 13 is a photograph of the LPCB
which consists of a number of compartments, namely shutter, window, collimating tube,
platform, stirring plate, lamps and power supply source. The MPCB was equipped with
the same type of components.
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Figure 13 : Low pressure collimated beam

Moreover, Petri dish attached to this bench scale apparatus was perfectly placed in its
position to calculate Petri factor, a shutter and a stopwatch were used to monitor the
exposure time, and a radiometer was used to measure the irradiance reading. Depending
on the required volume, 5.5 cm (for 50-55 mL samples) diameter Pyrex crystallizing
dishes (60x35) were used as Petri dish. The dish was placed on a vertically adjustable
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platform that supported a stir plate as shown in the above figure. Samples were placed in
the Petri dish as specified. The dish with sample solution was centered directly below the
collimating tube and was gently stirred by using a magnetic stir bar. The radiometer was
connected to a UV sensor head, the detector, which typically measures irradiance or
fluence rate as a function of the distance from the UV lamp. To measure the irradiance at
the surface of the water in the Petri dish, the radiometer detector head was located at the
same height as the surface of the water in the dish. Radiometers and detectors are
typically calibrated by manufacturer where these devices are usually re-calibrated at least
a year. It should be mentioned that in a collimated beam the irradiance and fluence rate
are the same (Bolton and Linden 2003).

Parameters for fluence rate determination: In this work, UV doses were specified based
on literature study for the facilitation of the experimental work and the corresponding
exposure times were calculated from the measurement parameters and using (4.1).

UV dose ( mJ/ cm2 )=

x t . . . .......... . (4.1)

Where E'avg denotes average irradiance (mW/cm2) and t represents exposure time in
second.

Measurement parameters include the size of the Petri dish, the sample volume, the sample
depth, absorption coefficient, radiometer readings, central irradiance, and the distance
from center of the lamp to the sample solution surface. This distance was different for
each LPCB (as three LPCBs were used) as well as for MPCB. Measurement parameters,
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and a standard well known spreadsheet outlined by Bolton and Linden (2003) were used
to calculate average irradiance.

Applied UV doses: The UV doses were selected starting from the typical germicidal UV
fluence o f 40 mJ/cm 2 to the highest fluence based on a number of literature studies. In the
present study the applied LP-UV doses were 40, 150, 300, 500, 1000 mJ/cm 2 and the
MP-UV doses were 40, 300, 500, 700, 1000 and 2000 mJ/cm2. These higher fluences are
all in a range comparable to UV fluences applied in other UV/H2O2 studies. For example,
UV flences up to 1700 mJ/cm were used in the study by Pereira et al. (2007). In general,
a longer exposure time is required with the LP lamp than with the MP lamp to achieve the
same fluence. Thus, for practical reasons, the LP lamp was used to test a lower range of
fluences than the MP lamp.

Measurement of average UV irradiance in water: The radiometer detector only provides a
measure of the irradiance incident on the water at the center of the beam; hence, several
factors must be considered in order to obtain average irradiance in the water. Average
irradiance in water provides an estimate of the average fluence rate which is used in (4.1)
to calculate exposure time. The average irradiance in water is obtained using the
following equation according to Bolton and Linden (2003),

E'avg = E0 X PF X R F X D F X WF ............ . (4.2)

Where, E^vg= average fluence rate (mW/cm2),
Eo= radiometer reading at the center o f the Petri dish (mW/cm )
PF= Petri Factor
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RF=Reflection Factor
DF=Divergence Factor
WF=Water Factor
Petri Factor (PF) is specific to the geometry of the CB. It is defined as the ratio of the
average of the incident irradiance over the area of the Petri dish to the irradiance at the
center of the dish. PF is usually greater than 0.9 (90%). In this study three LPCB were
used for which PF ranged from 0.940-0.967 and for MPCB the value was 0.945.

Reflection Factor (RF) is 0.975 and it represents the fraction of the incident beam that
enters the water.

Water Factor (WF) is defined as (4.3)

1 - 10-7^

W F = -— -— -------...
I n ( 1 0 ) X Ta

Ta is the total absorbance which is calculated from absorbance (cm 1) and path length
(cm) of the water in the Petri dish (wi). In this study, wi was 2.1 cm and 2.31 cm for the
sample volume of 50 mL and 55 mL, respectively. The absorbance of spiked LGW, UV
treated AUVEf and SW samples was measured (between 200 and 300 nm) using UV-Vis
Spectrophotometer before starting each irradiation experiment. This absorbance reading
was needed to calculate WF of a particular solution. During the UV/H 2O2 experiment, the
absorbance reading was taken after dosing the solutions with H2O2.

Divergence Factor (DF) is defined as (4.4)
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DF =

4 -,
dl w -hwl

Where,

diw = Distance from the center of the lamp to the surface of water solution

wi = Water path length

When a medium pressure UV lamp is used, an additional correction factor, the sensor
factor (SF), must be considered. SF is the sensitivity of the detector at 254 nm divided by
the weighted average sensitivity o f the detector over the 200-300 nm band. SF is almost
always greater than unity (Bolton and Linden 2003). In the present study the value was
1. 21 .

4.2.2 Sample Preparation and Processing
The targeted pharmaceuticals were selected for this study based on consumption and
environmental relevance. The structure and properties of the selected pharmaceuticals are
presented in Table 9 (Chapter 3). The spiking concentrations of the PhACs for the
degradation experiment were selected based on literature study and, the fact that these
PhACs are usually found at high concentration in WW, and to allow an investigation of
the potential of UV and UV/H 2O2 treatment for their removal from the considered water
matrices.
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Three types of water matrices were used as test water, and four experimental conditions
were applied for each set o f water matrix. Test water was prepared by spiking the stock
solutions of the selected PhACs into LGW, AUVEf and raw SW. AUVEf and raw SW
samples were obtained from GPCP and EAWTP, respectively. The pH and TOC
concentration in AUVEf were measured as 7.37 and 7 mg/L, respectively. The water
quality parameters of the water matrices are presented in chapter 3. In order to prepare
the test water for UV and UV/H 2O2 treatments, aliquots of each stock solution (100
mg/L) was added to a 50 mL flask. For AUVEf and SW, samples were filtered with 0.45
pm membrane filter prior to preparing the test water. The initial concentration of the
PhACs in the tested water was 200 pg/L. A sample volume 50 mL was used for
irradiation during UV treatment, whereas a 55 mL sample volume was used during
UV/H 2O2 treatment.

After treatment, samples from each experiment were processed in duplicate as follows. A
50 mL sample aliquot was acidified to pH of about 2 using hydrochloric acid prior to
extraction. The treated and untreated samples were preserved at 4°C in the dark, and due
to time constraints extraction and analysis were performed the following day. Each and
every time an untreated and a blank sample were run along with the treated samples. The
extraction and analysis were carried out according to the procedure described in Chapter
3.
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4.2.3 Absorbance Spectra o f the Analytes
In studies of the UV inactivation of microorganisms, there is the need to first determine
the UV response of a given microorganism in the water matrix in which the organism is
found or is spiked (Bolton and Linden 2003). To measure UV absorbance of each PhACs
in water solution, targeted analytes were spiked in LGW at a concentration of 200 pg/L.
An UV-visible spectrophotometer was used to determine the UV absorbance spectra of
the sample solutions. In order to undergo photolysis, the behaviour of the analytes
response to UV irradiation at the emitted wavelengths, and the structure of the analytes
play important role.
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Figure 14: UV absorbance spectra plot of (a) ibuprofen (b) naproxen
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290

300

Due to the low absorbance of irradiation at the 254 nm wavelength by the PhACs, it was
expected that they would undergo minimal photolysis when exposed to low pressure UV
irradiation. Figure 14 shows the target PhACs have slight absorbance in the 270-290 nm
range, and absorbance maximum below 240 nm, which suggested that medium pressure
UV irradiation would be more effective. In addition, the present study investigated
decadic molar absorption coefficients of the selected pharmaceuticals (section 4.2.4) to
understand their photodegradation characteristics. The results of absorbance spectra and
decadic molar absorption coefficients show that ibuprofen and naproxen absorb light
mainly at lower wavelengths and their absorbance is minimal at 254 nm.

4.2.4 M olar Absorption Coefficients ( e)
The UV energy absorption of an organic compound can delineate the degradation effect
under its exposure to photodegradation. The molar absorption coefficient is a measure of
how strongly a compound absorbs light at a given wavelength. A comparison of the
absorption coefficients for the targeted pharmaceutical compounds may provide an
explanation for the differences in direct photolysis rates as well as for the differences
observed between the MP and LP lamps. According to Schwarzenbach et al. (2003), the
decadic molar absorption coefficient, Si(k) can be defined as a “measure of the probability
that the compound i absorbs light at a particular wavelength”. The unit for £;(>.) is N f’cm"
\ Using a spectrophotometer, the absorbance A of a solution of the compound can be
measured as a function of wavelength in a cuvette exhibiting a specific width (1, 5 or 10
cm) (Schwarzenbach et al. 2003). From the absorbance of the solution, s,(À) can be
calculated as (4.5)
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A(X) = s i(X).Ci.l... ... ... ... (4.S)

Where, A(k) is the absorbance of the solution of the compound, C, is the concentration of
the compound i in moles per liter (M), and l is the path length of the light in the solution
expressed in centimeters. In the spectrophotometer, it can be assumed that the path length
of the light within the cell is almost identical with the cell width (Schwarzenbach et al.
2003).

To obtain molar absorption coefficients of the investigated pharmaceuticals (ibuprofen
and naproxen), each PhACs was spiked into LGW to prepare 200 pg/L solutions.
Afterwards, the prepared water solution was poured into a 1 cm quartz cuvette and the
UV absorbance (cm 1) was taken using UV/Vis Spectrophotometer. In all instances,
absorbance values were corrected for a blank which was done with LGW. Thus, molar
absorption coefficient was calculated by dividing the measured UV absorbance (cm 1) by
a molar concentration (M).
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Figure 15 shows the decadic molar absorption coefficient (s) for the selected PhACs
where 8 is a function of wavelength. The calculated s for ibuprofen and naproxen at a
wavelength 254 nm was 1031 N f'cirf1 and 5080 M"'crrf1 respectively, which showed e
for ibuprofen was almost five times lower than that of naproxen. The obtained s of
naproxen in this study was found 5080 M ^cnf1, which agrees well with the value of 4900
lyr'cm"1reported by Pereira et al. (2007), but is higher than the 3961 IVT'cm'1 measured
by Kim et al. (2009).
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4.2.5 H20 2 Stability Study
Hydrogen peroxide stability study in water matrices is required to check the change of its
concentration with time. Usually, raw water contains different kinds of organic matters
which can react with hydrogen peroxide (H20 2) and thus can affect its concentration.
Therefore, hydrogen peroxide stability was investigated in this study to determine the
appropriate dose during UV/H20 2 treatment. H20 2 doses were selected to reflect
environmental concentrations, and to ensure that it does not hinder the degradation
process as H20 2 itself can act as -OH radical scavenger when present in excess amount.
Hydrogen peroxide (30%) was dosed at 3 mg/L, 10 mg/L and 20 mg/L depending on the
experimental conditions (see Table 16). These doses were selected based on their large
application in full-scale water treatment plants and for the above reasons. From a
hydrogen peroxide (30%) stock concentration of 2.22 mL aliquot was taken to prepare 3
mg/L H20 2 concentration during UV/ H20 2 degradation experiment in LGW. However,
the measured hydrogen peroxide dose was found to be 2.9 mg/L.
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(a)

(b)

(c )

Time (hr)

Figure 16: Hydrogen peroxide stability investigated at different concentration in (a)
LGW, (b) SW and, (c) AUVEf

Hydrogen peroxide measurements were carried out following the triiodide ( I 3 )
spectrophotometric method as outlined by Klassen et al. (1994). According to their
method, H20 2 reacts with potassium iodide (KI) in a buffered solution containing
ammonium molybdate as a catalyst. The absorbance of the triiodide ( I 3 ") product was
measured at 351 nm and the H20 2 residual concentration was calculated by (4.6).
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Table 16 : Measured concentrations and applied doses of hydrogen peroxide in
water solution
Water

Experimental

H20 2 concen as

H20 2

Matrix

conditions

desired

as measured

sample solution

o fH 20 2*

(mg/L)

(mg/L)

(mL)

(pL)

l p -u v / h 2o 2

3

2.9

1000

2220

MP-UV/ H20 2

3

2.9

1000

1600

LP-UV/ H20 2

10

10.01

55*1

1440

MP-UV/ H20 2

10

10.04

55

1440

LP-UV/ H20 2

10

9.87

55

1100

MP-UV/ H20 2

3

3 .3

55

315

10

9 .9 4

55

1070

20

19.29

55

1230

LGW

SW

AUVEf

*:

Spiking doses

o f H20 2 used

using

different

concen

Volume

of

the

Spiking

doses

stock concentration o f Hydrogen peroxide

55 ml volume used for real matrix to measure H20 2 before and after irradiation

From the results of the stability study (Figure 16) it is observed that H2O2 stability is not a
concern in LGW. However, in the field or real samples hydrogen peroxide concentration
decreased with time, although it was slow. In the experiments with UV treated
wastewater effluent, degradation occurred slowly. However, for raw wastewater this
finding carries with it some implications as raw wastewater is more complex than UV
stream effluent. Based on the above reasons, hydrogen peroxide was spiked into one litre
of prepared LGW solution at once. While working with either AUVEf or SW, for each 55
mL prepared solution hydrogen peroxide was added according to the required dose as
shown in Table 16.
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UV Transmittance (UVT): UV Transmittance (UVT) is an important parameter to
consider during design and implementation of UV systems (USEPA 2003). UVT is a
measure of the fraction of incident light transmitted through the water column. The UVT
is usually reported for a path length of 1 cm and as a percentage. UVT can be calculated
from UV absorbance using the following equation

% UVT =

1 0 0 X 1 0 ~ A ... ... ... ... ( 4 . 7 )
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Figure 17: Percentage UV Transmittance in three water matrices under spiked
condition
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In the present study, UV absorbance readings were taken over the wavelengths, X= 200300 nm for the water matrices with their spiked conditions. Thereafter UV Transmittance
characteristics of the three water matrices in their spiked conditions were investigated
(Figure 17).

4.3

Degradation Results

Treatment experiments were performed to investigate the behaviour or to analyze the
nature of the degradation o f ibuprofen and naproxen in LGW, AUVEf, and SW under
spiked conditions. The process employed were UV photodegradation (LP and MP) with
and without the addition of hydrogen peroxide. Therefore, each set of water matrix was
treated under four types of experimental conditions. For practical reasons pertaining to
required exposure times, the experiments with the LP lamp were limited to a fluence of
1000 mJ/cm2 as fluence values higher than this would have required exposure times up to
several hours long. MP requires less exposure time, hence a reasonable fluence of up to
'j

2000 mJ/cm was employed.

The objectives of the experiments were to assess the influence of various water quality
parameters on the removal process, and to estimate the effectiveness of the treatment
conditions. Both AUVEf and SW quality parameters were measured which gave an
indication of the presence of substances in the water that could scavange hydroxyl
radicals or compete for UV irradiation.
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4.3.1 Photodegradation Treatm ent for Ibuprofen
Figure 18 illustrates the percentage removal of ibuprofen in LGW under different sets of
treatment conditions.
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Figure 18 : Average percentage removal (initial concentration, C0=200 pg/L) of
ibuprofen in LGW

Figure 18 shows that the LP-UV process is less effective as it can remove around 40% at
its maximum. It has already been mentioned that 1000 mJ/cm dose requires long
exposure time which may not be suitable in practical field. It is also apparent that LPUV/H 2O2 is not much more effective in reducing the concentration of ibuprofen.
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However, MP-UV seems to be an effective treatment process as it achieved more than
80% removal, while MP- UV/H2O 2 appears to be the best suited process for this matrix as
it yielded more than 90% removal. As this experiment was limited to 3 mg/L, it can be
inferred that a higher concentration as well as slightly higher dose can reduce ibuprofen
concentrations to below detection limit.

Figure 19 : Average percentage removal (Co=200 pg/L) of ibuprofen in AUVEf

Figure 19 demonstrates the percentage removal of ibuprofen in AUVEf matrix. The
legend of the figure depicts that there are six different experiments presented here; among
them, LP and LP-UV are less effective in removing the pharmaceuticals to a reasonable
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limit. Although LP-UV/H2O 2 shows an increasing trend to 80% removal at 1000 mJ/cm ,
it can be estimated that the desired level of removal requires a very high dose and thus the
application time would be too long. The figure clearly indicates that the MP-UV and MPUV/H 2O2 are more effective in removing the selected PhACs to the desired level. It is
also apparent from the data in the figure that high concentrations of H2O2 (20 mg/L) can
remove the target compounds most effectively below detection limit at a reasonable dose
of 1000 mJ/cm2 (23 minute). MP with low H2O2 doses was also able to remove ibuprofen
by more than 95%, but still required a higher dose.

Figure 20 shows the results from the experiment with surface water under LP and MP
direct and indirect photolysis. For this matrix LP-UV with 10 mg/L hydrogen peroxide is
found to be more effective than the MP-UV alone, although both of them are not capable
of removing the ibuprofen below the detection limit even with higher UV dose and at the
same concentration of H2O2. Figure 20 further illustrates that, among all the treatments,
MP-UV/ H2O2 is very effective in reducing the initial ibuprofen concentration above
96%. However, it can be expected that if we could apply MP with H2O2 at 20 mg/L the
process can bring it down to the detection limit.
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Figure 20 : Average percentage removal (Co=200 pg/L) of ibuprofen in SW
The percentage removal of ibuprofen in various water matrices under the identical
experimental condition is compared in Figure 21. In this case the LP and MP cases alone
are compared for three water matrices. Figure 21 demonstrates that the percentage
removal is higher in AUVEf, followed LGW for both LP and MP case. This trend can be
explained as follows.

In surface water, the degradation of these PhACs would probably be lower since
dissolved organic matter (NOM) in the water will compete with the PhACs for UV light.
The situation is different for AUVEf.
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Figure 21 : Average percentage removal (Co=200 pg/L) of ibuprofen in three water
matrices under direct photolysis

As the work was conducted with UV treated effluent (wastewater effluent from the UV
channel), NOM might not have competed for UV light when exposed to UV irradiation
with the PhACs. Hence, higher degradation is observed in AUVEf. On the other hand,
LGW presents the best case scenario, so the degradation can be expected to be higher for
the PhACs; however, the degradation in LGW is still lower than AUVEf as shown in
Figure 21. This trend is similar for MP-UV photodegradation as shown in Figure 21. It
can be assumed that some radical species may generate from the NOM when they go
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under photolysis, where the radical species facilitates the degradation process. This
phenomenon can be explained by the absorbance spectra measured from water solution
(AUV wastewater effluent solution provides higher absorbance value given in Appendix
B). On the other hand, water absorbance spectra measured from SW solution is close to
that o f LGW (Appendix B).

Wastewater generally contains more complex organic

matters and may generate more radical species than the other water matrices. The
presence of natural organic matter (NOM) would compete with the PhACs for UV light
(Pereira et al. 2007).

4.3.2 Degradation and Rem oval o f Naproxen using UV/H20 2
AOP
Average percentage removal of naproxen in LGW is presented graphically in Figure 22.
In this case experiments were performed using LP-UV, MP-UV, LP-UV/H2O2 and MPUV/ H 2O2 as treatment scenarios. The applied H2O2 dose was 3 mg/L for the indirect
photolysis. A comparison of the data in Figure 22 (naproxen) with those in Figure 18
show that percentage removal using LP-UV and LP-UV/ H2O2 was greater for naproxen
than for ibuprofen as naproxen is more susceptible to photodegradation. Although
naproxen absorbance is minimal at wavelength 254 nm, its decadic molar absorption
coefficient is five times higher than that of ibuprofen. At the initial dose 40 mJ/cm , the
percentage removal of naproxen by LP-UV alone is 20% compared to 40% for the MPUV/ H 2O 2 (Figure 22). Although the percentage removal difference is not large at lower
doses for LP direct and indirect photolysis, it is significantly larger at the higher dose of
1000 mJ/cm2.
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Figure 22 : Average percentage removal (Co=200 pg/L) of naproxen in LGW

Among all the experimental conditions, MP-UV/H 2O2 yielded the highest percentage
removal as shown in Figure 22. The figure also shows that MP direct and indirect can
degrade effectively at the desired level within 15 minutes.

As the identification and degradation in wastewater was the main target, the number of
experiments carried out on that was higher due to the application of different H2O2 doses.
As explained earlier, LP degradation of naproxen is greater than that of ibuprofen.
Percentage removals by LP-UV with the addition of 10 mg/L FI2O2 and MP-UV alone are
very close as shown in Figure 23. The percentage removal by LP-UV with the addition of
106

10 mg/L H2O2 and higher doses substantially increases the degradation due to the higher
•OH radical generation. Though LP-UV removes 80% of the naproxen at a fluence of
1000 mJ/cm , it seems it is difficult to reduce the concentration below the detection limit
even at higher fluences. Generally, it can be concluded that the application of the MP-UV
with different H2O2 doses can actively degrade naproxen in a wastewater matrix.
Although the results show that MP-UV plus 20 mg/L and 10 mg/L H2O2 can degrade
naproxen under different fluences, the higher dose achieves degradation to concentrations
below the detection limit (MDL) at 2000 mJ/cm2.

Figure 23 : Average percentage removal (Co=200 pg/L) of naproxen in AUVEf
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From the results it can also be stated that the addition of 10 mg/L H 2O2 reduces the
naproxen concentration close to MDL level with the optimum dose applied.

Figure 24 : Average percentage removal (Co=200 pg/L) of naproxen in SW

As illustrated in Figure 24, considerably high removals of naproxen are obtained in the
surface water when 10 mg/L of H 2O 2 is added, likely due to the production of the highly
reactive hydroxyl radicals. Even though the removal obtained by indirect photolysis is
30% at the lowest applied UV fluence, the compound is degraded to 98% under the same
process at the highest UV fluence (1000 mJ/cm2) , where the LP-UV/H2O2 process is
observed to achieve 25% higher removal than LP-UV alone at the same fluence.
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Although LP-UV with 10 mg/L of H 2O 2 can degrade naproxen up to 98% (which was
required 123 minutes irradiation period/time), it would probably not be feasible to use it
to degrade the compound down to the MDL level due to the long application time (> 123
minute). The degradation by MP-UV with the addition of 10 mg/L of H2O2 is lower
(probably due to some error in sample preparation) at the few initial fluences in
comparison with the results for LP-UV with 10 mg/L of H 2O2, the former process only
can degrade the compound up to MDL within 26 minutes. The results suggest that the
MP-UV alone may not be a suitable process for removing naproxen down to the MDL
level even at high fluence (> 2000 mJ/cm ).

The direct photolysis results obtained in the LGW, SW and AUVEf for the removal of
naproxen are compared in Figure 25. The results include both LP and MP direct
photolysis without the addition of H2O2. Figure 25 shows that the initial degradation is
lower in LGW than in SW, but degradation at the higher fluences is increased in LGW,
probably due to the competition from other organics present in SW. Among the three
water matrices, wastewater shows the highest degradation of naproxen for both LP-UV
and MP-UV treatments. The enhanced photodegradation in wastewater can be explained
by less consumption of UV energy to NOM and/or by an indirect production of radicals
from reaction of UV with NOM.

109

Figure 25 : Average percentage removal (Co=200 pg/L) of naproxen in three water
matrices under direct photolysis

It may be inferred from Figure 25 that the generation of -OH radical species from natural
organic matter (NOM) present in surface water would probably not significantly enhance
naproxen degradation. As said earlier, this may be due to SW absorbance spectra.
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4,4

Conclusions

This work studied the degradation of two widely used NSAIDs, ibuprofen and naproxen,
by UV based direct and indirect photolysis. Fundamental photolysis parameters were
determined in LGW for these compounds and their removal from different water matrices
was evaluated during direct and indirect photolysis experiments. Absorbance (A) and
decadic molar absorption coefficient (e) are the parameters that influence the direct
photolysis of a compound. Though ibuprofen and naproxen do not show an absorbance
(A) peak at the 254 nm wavelength, naproxen showed higher removal during direct and
indirect photolysis. Its rapid degradation during UV photolysis could be attributed to the
relatively high molar absorption coefficient (s) compared to that of ibuprofen.

Several measures were taken to control the quality of the results. Duplicate irradiations
were carried out for each set of treatment conditions. After the treatment work, most of
the treated samples were analyzed in duplicate. Samples were exposed to the UV fluence
in a random order. This random order placement of samples was done according to the
recommendations of Bolton and Linden (2003). Blank samples and standards were
processed along with the treated samples. The inclusion of standards ensured reasonably
high sample quality when treated samples were stored overnight prior to extraction. The
spiked untreated samples with known concentrations were analyzed to obtain recovery
rate that varied within 80%-l 10%.

At the highest LP-UV fluence of 1000 mJ/cm2, the degradation of ibuprofen by direct
photolysis was within 35%-52% of its initial concentration in the three water matrices,
although naproxen concentration was reduced by approximately 73%-79%. On the other
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hand using the same fluence for MP, ibuprofen concentration was reduced by 69%-80%
and naproxen by 90%-96%. Eventually UV/H2O 2 AOP reduced dose and time required to
remove PhACs from water matrices. Therefore, the study found that the degradation of
PhACs was enhanced when using the UV/H2O 2 AOP treatment as it reduces time and
dose.

As shown from the degradation results, the percentage removals of the PhACs spiked into
AUVEf were higher than those obtained when the compounds were spiked into LGW or
SW. Such improved photodegradation of the PhACs in AUVEf can be explained either
by the less consumption of UV energy by natural organic matter (NOM) or by an indirect
production of radicals from the reaction of UV with NOM in this matrix. This
observation is similar to those reported by other researchers. For example, Doll and
Frimmel (2003) reported that photochemical degradation of carbamazepine in surface
water from Lake Hohloh in southwest Germany was enhanced by the presence of natural
organic matter (NOM). In the present study, it may be inferred from the results that the
degradation of the PhACs could either decrease due to the competition with NOM, or
increase due to less competition for the consumption of UV energy by NOM as well as an
indirect formation of OH radicals from reaction of UV energy with NOM. Therefore, it
can be expected that in AUVEf, the hydroxyl radicals acted as a precursor during UV
photolysis and thus expedited percentage degradation of the PhACs.
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CHAPTER 5
KINETIC STUDY

5.1

Introduction

The photodegradability of two pharmaceuticals using LP and MP UV lamps emitting light at the wavelengths of 253.7 nm and over a broad range of wavelengths of 200-600
nm (Stefan 2004), alone and with the H2O2 for enhanced degradation were investigated in
chapter 4. As mentioned previously, the pharmaceuticals (ibuprofen and naproxen) were
selected on the basis of consumption and environmental relevance, and were spiked with
three tested water matrices for bench scale UV treatment. In this chapter, degradation rate
constants of the two PhACs from UV and UV/H 2O2 (LP and MP) treatment are
calculated, and the UV doses required for 90% removal of the pharmaceuticals in three
water matrices are estimated. The calculation of the rate constants are carried out using
best fit curves (Appendix C). Thus, the first order rate constant k (either time based or
fluence based) values are obtained for UV and UV/H2O2 treatment in UV treated
wastewater effluent (AUVEf), raw surface water (SW) and laboratory grade water
(LGW).
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5.2

Determination of Kinetic Rate Constants

The determination of the kinetic rate constant is based on a simple mathematical
derivation and assumption. The differential and linearized forms of the first order rate
constant equation (Schwarzenbach et al. 2003) can be expressed as (5.1) and (5.2).

dC^
= b r
dt

(5.1)

ktt

Where,

C ph

(5.2)

is the concentration of pharmaceutical compound, kt represents the time based

first order rate constant, and CPho is the concentration at initial time, i.e to=0. Generally kt
can be written as (5.3).

f

1 11

tit

lit

tit

Where kdt is the direct photolysis first order rate constant, and klt is the indirect first order
rate constant. When the experiment is carried out using direct photolysis (UV), then kdt
can be determined using (5.2). The use of indirect photolysis (UV/H2O2) in the
experiment provides kt from the same equation (5.2). Thus, the indirect rate constant klt
can be figured out by subtracting kdt from kt .

Similarly fluence based rate constant equation can be written as (5.4) and (5.5).

dC•ph
df

~ k f Cph ■" -
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[^pfco]
Where initial applied fluence, fo=0 and the other variables as before.
Thus, fluence based rate constant kf can also be written as (5.6).
kjp

¡(¿f "I-

mi

in ttt

mi (5.6)

It has been previously mentioned that the applied LP-UV fluences were 40, 150, 300,
500, 1000 mJ/cm2, and MP-UV fluences were 40, 300, 500, 700, 1000 and 2000 mJ/cm 2
in the experiments. A plot of the results from experiments using the LP and MP lamps
and the subsequent linear regression analysis provided estimates of kdfor kdt. Similarly, a
plot of the results from experiments using the LP lamp as well as MP lamp at a range of
fluences and with various doses of H2O2 followed by linear regression analysis yielded
estimates for kf or kt.

The fluence and time based rate constants obtained in the water matrices as a result of
direct and indirect photolysis (LP and MP) are presented in Table 17 and Table 18
respectively for ibuprofen and naproxen. For a particular water matrix, the first order rate
constants are found to agree well with the trend of degradation. It can be stated from
Tables 17 and 18 that the process with higher removal give higher values of kf and kt,
while the lower removal process yields lower values. In LGW, both computed kf and kt
show that MP-UV/H2O2 achieves the highest degradation among the four experimental
conditions. Similar conclusions may be drawn from the AUVEf and SW results (Tables
17 and 18).

A comparison of the rate constants among the various water matrices shows that, fluence
based kinetic rate constants agree well with the percentage degradation. However, there
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are some observed differences when the comparison is made using time based rate
constants. For example, time based rate constants for AUVEf are sometime found to be
lower than values for SW or LGW. As the WW matrix is a complex matrix compared to
the other two, there may be a number of reasons for the variation in rate constant. One
possible reason is the difference in solution water absorbance spectra (see Appendix B).
The highest absorbance spectra resulting from WW provides the lowest average
irradiance (use of (4.2)).

Consequently, the applied times for a particular dose are

different in the water matrices. Not much work has been done to compare with fluence
based and time based kinetic constants obtained simultaneously during the degradation of
PhACs in different water matrices. Thus more work needs to be done to understand the
factors or parameters controlling rate constants, such as irradiation condition, pH and
temperature.

The results presented in this chapter for naproxen can be compared to results reported by
Pereira et al. (2007). In the present study, the value of kf obtained from LP-UV/H2O2
treatment for naproxen in LGW is 0.00215 cm2/mJ. For a similar matrix, Pereira found kf
to be 0.0119 cm /mJ when they applied 10 mg/L of H2O2 and a fluence range of 40
mJ/cm to 1700 mJ/cm . In addition, the rate constant for naproxen, 0.0037 cm /mJ is
close to the value of 0.0033 cm2/mJ observed by Pereira et al. (2007) during MP-UV
direct photolysis in LGW. The value of kf for the LP-UV/H2O2 experimental condition is
0.00378 cm /mJ in SW in the present study, while Pereira et al. (2007) reported a value
of 0.003 cm /mJ. For MP-UV direct photolysis of naproxen in SW, the obtained rate
constant (0.00286 cm2/mJ) is closer to that of 0.0025 cm2/mJ.

116

Table 17 : Fluence and time-based rate constants obtained by direct and indirect
photolysis o f ibuprofen
LP-UV
Matrix
LGW

AUVEf

SW

MP-UV

l p -u v / h 2o 2

m p -u v / h 2o 2

kdf

kdt

kf

kt

kdf

kdt

kf

kt

(cm2/mJ)

(min'1)

(cm2/mJ)

(m in 1)

(cm2/mJ)

(m in ’)

(cm2/mJ)

(m in 1)

4.40E-04

3.18E-03

1.04E-03

7.8E-03

8.29E-04

.

1.23E-03

1.09E-01

(H20 2:
3ppm)

(H20 2:
3ppm)

(H20 2:
3ppm)

(H20 2:
3ppm)

1.51E-03

8.4E-03

1.32E-03

5.5E-02

(H20 2:
1Oppm)

(H20 2:
1Oppm)

(H20 2:
3ppm)

(H20 2:
3ppm)

1.82E-03

7.68E-02

(H20 2:
1Oppm)

(H20 2:
lOppm)

4.66E-03

1.97E-01

(H20 2:
2 Oppm)

(H20 2:
20ppm)

1.47E-03

1.09E-01

(H20 2:
1Oppm)

(H20 2:
1Oppm)

7.22E-04

3.73E-04

4.38E-03

3.00E-03

1.29E-03

1.02E-02

(H20 2:
lOppm)

(H20 2:
1Oppm)

1.42E03*

7.64E-04

7 08

E- 0 2

6.24E-02

5.73E-02

* Two data were not available during MP-UV experiment in AUVEf

As seen from the tables, average first order rate constant for the PhACs investigated
increases by a factor that ranges from 1.21 to 1.69 (naproxen) and 0.93 to 3.28
(ibuprofen) by H2O2 addition during MP-UV treatment using AUVEf. During LP-UV
treatment the abovementioned factors are increased by a factor of 2.09 for ibuprofen and
2.91 for naproxen. In a study by Kim et al. (2009), the rate constant value for a number of
pharmaceuticals investigated during LP-UV and LP-UV/H2O2 treatment was increased by
a factor that ranged from 0.91 (ketoprofen) to 5.91 (metoprolol) in experiments
conducted using secondary effluent wastewater spiked with these compounds. Among the
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pharmaceuticals studied by Kim et al. (2009), the rate constant for naproxen increased by
a factor 3.84.

Table 18 : Fluence and time-based rate constants obtained by direct and indirect
photolysis of naproxen
Water
Matrix
LGW

AUVEf

SW

LP-UV

l p - u v / h 2o 2

MP-UV

MP-UV/H20 2

kdf

kdt

kf

kdt

(m in 1)

(cm2/mJ)

kt
(min'1)

kdf

(cm2/mJ)

(cm2/mJ)

(m in1)

kf
(cm2/mJ)

k,
(m in')

1.32E-03

9.6E-03

2.15E-03

1.74E-02

3.66E-03

3.06E-01

3.86E-03

3.12E-01

(H20 2:
3ppm)

(H202:
3ppm)

(H20 2:
3ppm)

(H20 2:
3ppm)

4.43E-03

2.4E-02

3.62E-03

1.51E-01

(H20 2:
1Oppm)

(H202:
lOppm)

(H20 2:
3ppm)

(H20 2:
3 ppm)

4.04E-03

1.7E-01

(H20 2:
1Oppm)

(H20 2:
1Oppm)

5.07E-03

2.14E-01

(H20 2:
20ppm)

(H20 2:
20ppm)

4.03E-03

3.00E-01

(H20 2:
1Oppm)

(H20 2:
1Oppm)

1.52E-03

1.27E-03

1.0E-02

1.08E-02

3.78E-03

2.95E-02

(H20 2:
1Oppm)

(H202:
1Oppm)

3.00E03*

2.86E-03

1.31E-01

2.14E-01

* Two data were not available during MP-UV experiment in AUVEf

Table 17 and 18 further indicate that in SW, the rate constants increased by a factor of 3.0
(naproxen) and 3.46 (ibuprofen) for LP lamp and 1.41 (naproxen) and 1.92 (ibuprofen)
for MP lamp. Pereira et al. (2007) showed that for naproxen the factor was 6.0 while
using LP lamp and 2.2 when MP lamp was used in SW.
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5.3

Estimation of 90% Degradation

Any target percentage of degradation for the pharmaceuticals can be estimated from the
rate constants or from the best fit equations (Appendix C). Thus, in this section two tables
are presented as examples. Table 19 and Table 20 summarize the fluences needed to
achieve 90% degradation for ibuprofen and naproxen in three water matrices by direct
and indirect photolysis. These sample degradation tables are applicable only for fluencebased rate constants. The exposure times in the aforementioned tables are calculated
based on (4.1).

UV doses required for degrading 90% of the initial concentration of ibuprofen in LGW
ranged from 5149 to 1669 mJ/cm2, and the corresponding exposure time decreased from
643 minutes to 20 minutes. Thus, the results suggest that UV/H 2O2 treatment using MP
lamp is the most effective method for the removal of ibuprofen in LGW. Similar type of
conclusion can be drawn for both AUVEf and SW as shown in Table 19. The study
shows that the applied highest dose of H2O2 with MP-UV can degrade ibuprofen by 90%
of its initial concentration, only within 7 minutes. Table 19 also demonstrates that under
similar experimental conditions, the required UV doses are the lowest for AUVEf
compared to the other two water matrices, though the corresponding times may not.
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Table 19 : U V exposure dose and tim e required fo r 90% degradation o f ibuprofen
Low pressure exposure

Medium pressure exposure

Water
matrix

UV
dose/mJ/
cm2 for
UV

Exposure
times/min
for UV

UV
dose/mJ/
cm2 for
u v / h 2o 2

Exposure
times/min
for
u v / h 2o 2

UV
dose/mJ/
cm2 for
UV

Exposure
times/min
for UV

UV
dose/mJ/
cm2 for
u v / h 2o 2

Exposure
times/min
for
u v / h 2o 2

LGW

5149

643.3

2083

262.25

2509

29.45

1669

20.52

(H20 2:
3 ppm)
AUVEf

3085

439.5

1465

(H20 2:
3 ppm)
216

1501

34.3

(H20 2:
10 ppm)

1335

32

(H20 2:
3 ppm)
878

20.85

(H20 2:
10 ppm)
301

7.12

(H20 2:
20 ppm)
SW

6129

811.82

1704

231

(H20 2:
10 ppm)

2797

37.7

1274

17.26

(H20 2:
10 ppm)

Similarly the UV doses and corresponding exposure times to degrade naproxen by 90%
of its initial concentration are presented in Table 20. The study illustrates that the UV
doses for naproxen are always lower than those of ibuprofen. As it is the case for
ibuprofen, the use of H2O2 also enhances the degradation rate as well as reduces the
exposure time for naproxen. Thus, the 90% degradation can be achieved only by applying
637, 358, and 663 mJ/cm 2 UV doses in LGW, AUVEf, and SW according to their highest
H2O2 application.
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Table 20 : UV exposure dose and time required for 90% degradation of naproxen
Low pressure exposure
Water
matrix
LGW

Medium pressure exposure

UV
dose/mJ/
cm2 for
UV

Exposure
times/min
for UV

UV
dose/mJ/
cm2 for
u v / h 2o 2

Exposure
times/min
for
u v / h 2o 2

UV
dose/mJ/
cm2 for
UV

Exposure
times/min
for UV

UV
dose/mJ/
cm2 for
u v / h 2o 2

Exposure
times/min
for

1601

217

1004

122.13

693

8.14

637

7.84

(H20 2:
3 ppm)
AUVEf

1387

197.55

526

UV/H2 O2

(H20 2:
3 ppm)
77.54

696

16

(H20 2:
10 ppm)

561

13.44

(H20 2:
3 ppm)
433

10.27

(H20 2:
10 ppm)
358

8.45

(H20 2:
20 ppm)
SW

1636

218.13

609

82.58

(H20 2:
10 ppm)

839

11.18

663

8.98

(H20 2:
10 ppm)

As seen from Tables 19 and 20, for UV treatment using low pressure, the UV dose
required for degrading the two targeted pharmaceutical compounds by 90% of their initial
concentration ranged from 1387 mJ/cm 2 to 3085 mJ/cm 2 in AUVEf, 1636 mJ/cm2to 6129
mJ/cm 2 in SW and 1601 mJ/cm 2 to 5149 mJ/cm 2 in LGW. The use of medium pressure
UV dose required for degrading these compounds by 90% of their initial concentration
ranged from 696 mJ/cm 2 to 1501 mJ/cm 2 in AUVEf, 839 mJ/cm 2 to 2797 mJ/cm 2 in SW
and 693 mJ/cm to 2509 mJ/cm in LGW. This suggests that long exposure time will be
required for their significant degradation in UV disinfection process. For MP-UV/ H2O2
treatment, these pharmaceuticals were degraded by more than 90% by UV irradiation for
7-20 minutes in AUVEf, 8-17 minutes in SW and 7-20 minutes in LGW. These results
showed that H2 O2 addition during UV treatment will be highly effective for enhanced
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degradation of pharmaceuticals. Moreover, MP-UV/ H2O2 AOP is the most effective
compared to LP-UV/H2O2 AOP, even though much higher UV dose may be required
when compared to UV disinfection at germicidal dose, which is 40 mJ/cm . The results
suggest that to achieve effective removal of the compounds using low pressure UV lamp,
a very high UV dose would be needed.

5.4

Conclusions

This chapter outlines the kinetic rate constant values for the results obtained from LP-UV
as well as MP-UV irradiation at a range of fluences with or without addition of hydrogen
peroxide (H2O2). The estimated kinetic parameters can be used to evaluate a target
percentage degradation of the two pharmaceuticals. The kinetic parameters for naproxen
compare well with those reported in previous studies. Both pharmaceutical compounds
underwent significant degradation by UV with hydrogen peroxide addition as shown
from their rate constants. Between the two PhACs, naproxen has the highest rate constant
for indirect photolysis (under both LP and MP UV treatments), suggesting that naproxen
reacts most readily with the hydroxyl radical. Based on the rate constants for ibuprofen,
degradation may be inferred to occur primarily by indirect photolysis. In the case of
naproxen, both direct and indirect photolysis are important but the latter is probably
dominant. Overall, the calculated kinetic rate constants confirm the importance of -OH
radical for the enhanced degradation of the PhACs, especially for ibuprofen.

As observed, although overall percentage removal in AUVEf is highest among the
matrices; degradation rates in AUVEf, using UV/H 2O2 treatment increased by a lower
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factor compared to experiments in LGW or SW. This may be due to the presence of *OH
radical scavengers such as HCO 3' and CO32' in AUVEf (the alkalinity of AUVEf was 161
mg/L as CaCC>3 compared to 98.51 mg/L as CaCC>3 for SW).

The first order rate constant k values vary slightly due to differences in some
experimental parameters such as lamp type, irradiation condition (on which average
irradiance and exposure time change), lamp to solution surface distance, solution water
absorbance spectra, water matrix pH, water path length (solution depth), sample volume,
hydrogen peroxide concentration, applied fluence dose as well as initial concentration of
the compounds in the solution. The molar absorbance and degradation of the compounds
depend on their pH and acid dissociation constant (pKa). Though the present study did not
investigate pH effect, previous studies (Andreozzi et al. 1999, Ikehata et al. 2006) have
shown that pH above the p/fa increases the molar absorbance of PhACs and facilitates the
degradation process. First order kinetics rate constant (time based or fluence based) can
be used to predict the extent of removal of these compounds in water matrices and
experimental conditions similar to those used in the present study.
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CHAPTER 6
CONCLUSIONS AND RECOMMENDATIONS

6.1
This

Conclusions
chapter summarizes the conclusions from this research and draws the

recommendations for further study. PhACs (ibuprofen and naproxen) that belong to anti
inflammatory drug group were investigated in this study due to their high usage around
the world and their reported occurrence in the aquatic environment.

For the identification o f the PhACs, water samples were collected from GPCP and
EAWTP in London, Ontario, Canada. It is observed that the obtained concentration of the
PhACs in the WW influent of London wastewater treatment plant varied from zero (or
below detection) to 17 pg/L. Although the concentrations of ibuprofen and naproxen were
low in these STPs at the time of the present investigation, it is possible that the
concentration may increase in future due to the increased consumption. As the STPs
under consideration do not use UV operation during winter and the PhACs do not
undergo natural photodegradaion, it is possible that they may find a pathway into natural
water and eventually into drinking water sources. Thus, there is the possibility that
humans could consume these compounds inadvertently on a daily basis, which could
produce subtle health effects over time.
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The thesis has evaluated the photodegradation characteristics and the effectiveness of
H2O2 addition for the degradation of the two PhACs during UV treatment under three
diverse water matrices at selected spiked concentrations. Higher degradations of the
PhACs were observed when H2O2 was added during UV treatment, due to the production
of the highly reactive OH radicals by H2O2 photodegradation. In particular, it was
observed that H2O2 addition was more effective in the degradation of PhACs with low k
values in UV treatment, suggesting that H2O2 addition can improve the degradation of
PhACs that are highly resistant to UV treatment, such as ibuprofen. Again, between the
two PhACs, naproxen showed higher removal during direct and indirect photolysis, as
would be expected because of its relatively high molar absorption coefficient which is
attributed mainly to direct UV photodegradation. The overall kinetic rate constant in
AUVEf is highest among the water matrices; however, for experiments involving
AUVEf, kinetic rate constant values in UV/H2O 2 treatment increased by a lower factor
compared to experiments using LGW or SW.

This thesis puts emphasis on the applicability of UV and UV/H2O2 processes as
technologies for wastewater reuse considering the removal of such recalcitrant
pharmaceutically active compounds based on disinfection effectiveness, decrease
effectiveness of ecological risk and the elimination or reduction of disinfection by
products. The results may be used by treatment plants that currently employ UV
treatment to optimize their processes and may also be used to compare efficiency of
direct or indirect photolysis with the use of other advanced oxidation process. Thus, these
findings have implications for wastewater and drinking water treatment plants and show
that a wide range of pharmaceutically active compounds can be degraded by the use of
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direct and indirect photolysis. The experimentally determined kinetic parameters can be
used to model the time and UV fluence based rate constants in diverse water matrices.

6.2

Recommendations for Future Research

To evaluate the presence of the PhACs at the Greenway Pollution Control Plant (GPCP)
regular monitoring for these compounds should be carried out for a longer period. Future
studies should address the possibility o f intermediate by-product formation during
photolysis of the two compounds and identify a feasible treatment process. As the
continuous exposure to the compounds could lead to long term health effects, more
research should be conducted to examine the environmental and human health impacts of
these PhACs.

No intermediate by-products of the PhACs were identified in GC/MS chromatogram
suggesting that, if these are formed, their retention time as well as their structures will
differ considerably from the parent compound. Further research should focus on the
intermediate by-product formation, and the potential impact of these intermediates by
products on environmental and human health. Detailed kinetic studies for the PhACs in
the three water matrices can further be investigated. In addition, optimization in terms of
cost for the proposed treatment processes could also be evaluated.
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Appendix A:
Water Quality Parameter data (July 28, 2010) of raw wastewater and UV treated
effluent for Greenway water treatment plant.
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Table B .l: H20 2 stability study data
LGW

Time,
t (hr)
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0
1
2
3
4
5
6

[H20 2]==
3ppm
3.05
3.00
3.00
2.99
2.97
2.98
2.96

[H20 2]=
lOppm
9.84
9.78
9.74
9.80
9.79
9.81
9.78

SW
[H 2o 2]=

15ppm
14.81
14.72
14.48
14.43
14.67
14.58
14.53

Time,
t (hr)

0
1
2
3
4
5
6

[H20 2]=
3ppm
3.03
3.00
2.98
2.97
2.94
2.86
2.77

AUVEf

[H 2 o 2]=

[H 2o 2]=

Time,

lOppm
9.69
9.68
9.70
9.65
9.61
9.59
9.54

15ppm
14.64
14.58
14.42
14.33
14.35
14.04
13.86

t (hr)

0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
5.5
6

[H20 2]=
3ppm
3.12
2.99
2.84
2.73
2.62
2.55
2.46
2.41
2.36
2.32
2.26
2.15
2.05

[H 20 2]=

[H 2o 2]=

lOppm
10.58
10.12
9.98
9.58
9.16
9.08
8.96
8.75
8.53
8.46
8.36
8.13
7.98

15ppm
16.53
16.06
16.04
15.68
15.31
15.19
15.05
14.92
14.81
14.63
14.41
14.35
14.3

Table B.2: Water spectra data of the sample solutions

.
.
Wavelength

LGW+
pharm

LGW+Pharm
“f~H20 2

AUVEf +
Pharm

AUVEf+Pharm
+H20 2

SW+Pharm

SW+Pharm+
H20 2

A,(nm)

A(lcm )

A(lcm )

A (lcm )

A( 1cm)

A(lcm )

A(lcm )

200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241

0.3124

0.5570
0.4710
0.3870
0.3190
0.2660
0.2230
0.1880
0.1590
0.1380

2.7930
2.8480
2.8910
2.9260
2.9510
2.9850
3.0000
3.0350
3.0530
3.0530
3.0580
3.0470
2.9890
2.9530
2.8630
2.7050
2.5620
2.3800
2.1890
2.0070
1.7810
1.6260
1.4590
1.3180
1.1770
1.0370
0.9270
0.8280
0.7380
0.6490
0.5780
0.5130
0.4590
0.4080
0.3590
0.3220
0.2910
0.2660
0.2420
0.2220
0.2060
0.1940

5.6661
5.3767
5.2089
5.0676
5.2252
5.1277
5.0858
5.0804
5.0104
4.8101
4.5687
4.5424
4.2536
4.1893
3.8591
3.6268
3.4259
3.1920
3.0016
2.7082
2.4703
2.2325
2.0715
1.8877
1.6592
1.4755
1.3634
1.2082
1.0944
0.9596
0.8413
0.7853
0.7059
0.6402
0.5711
0.4977
0.4511
0.4233
0.3763
0.3356
0.3030
0.2817

0.9861
0.8552
0.7500
0.6317
0.5360
0.4786
0.4352
0.3985

1.2545
1.0718
0.9036
0.7838
0.6784
0.5617
0.5018
0.4611
0.3958
0.3558
0.3102
0.2849
0.2670
0.2386
0.2197
0.2031
0.1916
0.1827
0.1735
0.1638
0.1578
0.1541
0.1488
0.1469
0.1450
0.1433
0.1420
0.1402
0.1391
0.1387
0.1362
0.1336
0.1308
0.1250
0.1133
0.1023
0.0973
0.0872
0.0770
0.0669
0.0588
0.0545

0.2666
0.2178
0.1774
0.1458
0.1192
0.0970
0.0790
0.0654
0.0542
0.0452
0.0382
0.0318
0.0274
0.0234
0.0206
0.0182
0.0164
0.0150
0.0140
0.0132
0.0124
0.0116
0.0110
0.0104
0.0096
0.0088
0.0078
0.0066
0.0054
0.0044
0.0038
0.0030
0.0022
0.0016
0.0012
0.0010
0.0006
0.0004
0.0004
0.0002
0.0002

0 .1 2 1 0

0.1080
0.0980
0.0900
0.0840
0.0800
0.0824
0.0796
0.0780
0.0778
0.0784
0.0800
0.0822
0.0848
0.0878
0.0902
0.0928
0.0948
0.0962
0.0972
0.0972
0.0954
0.0920
0.0860
0.0772
0.0664
0.0572
0.0474
0.0392
0.0312
0.0260
0.0206
0.0170
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0 .3 5 5 4

0.3153
0.2899
0.2762
0.2531
0.2327
0.2178
0.2014
0.1948
0.1819
0.1712
0.1625
0.1547
0.1505
0.1447
0.1408
0.1358
0.1342
0.1316
0.1309
0.1287
0.1253
0.1246
0.1236
0.1192
0.1138
0.1045
0.0963
0.0907
0.0797
0.0716
0.0631
0.0581
0.0541

Wavelength

LGW+
Pharm

LGW+Pharm
+ h 2o 2

A U V E f+
Pharm

AUVEf+Pharm
+H20 2

SW+Pharm

SW+Pharm+
h 2o 2

X(nm)

A(lcm )

A (lcm )

A(lcm )

A(lcm )

A(lcm )

A(lcm )

244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281

0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002

0.0102
0.0092
0.0084
0.0078
0.0076
0.0074
0.0072
0.0072
0.0070
0.0070
0.0068
0.0068
0.0068
0.0068
0.0070
0.0072
0.0074
0.0074
0.0074
0.0072
0.0072
0.0068
0.0068
0.0068
0.0068
0.0068
0.0068
0.0070
0.0070
0.0066
0.0062
0.0056
0.0054
0.0048
0.0046
0.0044
0.0042
0.0040

0.1710
0.1660
0.1630
0.1590
0.1570
0.1550
0.1530
0.1520
0.1510
0.1490
0.1490
0.1480
0.1470
0.1460
0.1460
0.1450
0.1450
0.1440
0.1430
0.1420
0.1410
0.1400
0.1390
0.1380
0.1370
0.1360
0.1340
0.1330
0.1320
0.1310
0.1280
0.1260
0.1250
0.1230
0.1200
0.1190
0.1170
0.1160

0.2311
0.2188
0.2118
0.2066
0.1980
0.1940
0.1910
0.1888
0.1879
0.1827
0.1821
0.1778
0.1761
0.1735
0.1742
0.1719
0.1687
0.1682
0.1681
0.1662
0.1660
0.1633
0.1606
0.1625
0.1594
0.1577
0.1584
0.1543
0.1525
0.1518
0.1511
0.1473
0.1474
0.1436
0.1407
0.1326
0.1349
0.1366

0.0430
0.0417
0.0409
0.0397
0.0381
0.0376
0.0379
0.0372
0.0362
0.0364
0.0357
0.0356
0.0350
0.0344
0.0338
0.0343
0.0335
0.0321
0.0331
0.0328
0.0324
0.0321
0.0306
0.0311
0.0295
0.0283
0.0290
0.0286
0.0291
0.0270
0.0262
0.0256
0.0248
0.0233
0.0230
0.0222
0.0211
0.0217

0.0418
0.0403
0.0387
0.0377
0.0366
0.0359
0.0355
0.0352
0.0348
0.0345
0.0342
0.0339
0.0336
0.0334
0.0332
0.0331
0.0332
0.0330
0.0329
0.0326
0.0322
0.0317
0.0314
0.0308
0.0305
0.0302
0.0301
0.0297
0.0293
0.0289
0.0281
0.0274
0.0266
0.0257
0.0250
0.0242
0.0237
0.0232
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282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300

LGW+
Pharm

LGW+Pharm
+ h 2o 2

A U V Ef+
Pharm

AUVEf+Pharm
+H20 2

SW+Pharm

A (lcm )

A(lcm )

A(lcm )

A(lcm )

A(lcm )

A( 1cm)

0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002
0.0002

0.0040
0.0036
0.0032
0.0030
0.0026
0.0022
0.0020
0.0018
0.0016
0.0014
0.0012
0.0012
0.0010
0.0010
0.0010
0.0010
0.0012
0.0010
0.0010

0.1130
0.1120
0.1090
0.1070
0.1050
0.1030
0.1000
0.0980
0.0960
0.0940
0.0920
0.0900
0.0880
0.0870
0.0850
0.0830
0.0820
0.0800
0.0790

0.1336
0.1316
0.1278
0.1250
0.1235
0.1200
0.1191
0.1155
0.1153
0.1076
0.1090
0.1076
0.1064
0.1019
0.1043
0.1008
0.1004
0.0976
0.0962

0.0205
0.0193
0.0189
0.0176
0.0172
0.0161
0.0150
0.0147
0.0144
0.0135
0.0132
0.0129
0.0118
0.0118
0.0114
0.0111
0.0102
0.0102
0.0098

0.0226
0.0223
0.0210
0.0206
0.0202
0.0192
0.0183
0.0178
0.0170
0.0164
0.0158
0.0153
0.0147
0.0144
0.0139
0.0136
0.0131
0.0128
0.0124
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SW+Pharr
H20 2

Table B.3: Percentage removal and standard deviation for the compounds

Compound

Ibuprofen

Water
Matrix

LGW

Experimental
Conditions

L P -U V

Degradation
Concentrations
(n=2)*'

uv
Fluence

h 20 2

(mJ/cm2)

(mg/L)

(Pg/L)

150

0

187

Dose

Average %
Removal*2

Standard
Deviation

9.88

3 .0 4

17.38

2 .1 4

24 .5

n/a

4 0 .9 6

13.23

4 8 .0 2

3.1 3

7 1 .8 8

n/a

5 6 .3 8

2.97

8 2 .4 2

5.45

3 8 .4 3

7.93

4 2 .9 6

5.1

49.21

6.74

7 8 .4 2
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*2: Calculated values are based on measured initial concentrations corresponding to 200 pg/L
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Figure C.l: Fluence-based rate constants obtained by direct and indirect
photodegradation in LGW using LP Lamp.
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Figure C.2: Fluence-based rate constants obtained by direct and indirect
photodegradation in AUVEf using LP Lamp.
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Figure C.3: Fluence-based rate constants obtained by direct and indirect
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Figure C.4: Fluence-based rate constants obtained by direct and indirect
photodegradation in LGW using MP Lamp.
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Figure C.5: Fluence-based rate constants obtained by direct and indirect (where
a=10 mg/L and b=20 mg/L) photodegradation in AUVEf using MP Lamp.
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Figure C.6: Fluence-based rate constants obtained by direct and indirect
photodegradation in SW using MP Lamp.
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Figure C.7: Time-based rate constants (s'1) obtained by direct and indirect
photodegradation in LGW using LP Lamp.

154

Figure C.8: Time-based rate constants (s'1) obtained by direct and indirect
photodegradation in AUVEf using LP Lamp.
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Figure C.9: Time-based rate constants (s'1) obtained by direct and indirect
photodegradation in SW using LP Lamp.
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Figure C.10: Tim e-based rate constants (s_1) obtained by direct and indirect
photodegradation in LG W using M P Lam p.
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Figure C .ll: Time-based rate constants (s’1) obtained by direct and indirect (where
a=10 mg/L and b=20 mg/L) photodegradation in AUVEf using MP Lamp.
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Figure C.12: Tim e-based rate constants (s'1) obtained by direct and indirect
photodegradation in SW using M P Lamp.
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